Polymeric Gels and Their Application in the Treatment of Psoriasis vulgaris: A Review

Agnieszka Kulawik-Pióro * and Małgorzata Miastkowska *

Department of Chemical Engineering and Technology, Cracow University of Technology, Warszawska 24, 31-155 Cracow, Poland
* Correspondence: agnieszka.kulawik-piero@pk.edu.pl (A.K.-P.); malgorzata.miastkowska@pk.edu.pl (M.M.);
Tel.: +48-1-2628-2740 (A.K.-P.); +48-1-2628-3072 (M.M.)

Abstract: Psoriasis is a chronic skin disease, and it is especially characterized by the occurrence of red, itchy, and scaly eruptions on the skin. The quality of life of patients with psoriasis is decreased because this disease remains incurable, despite the rapid progress of therapeutic methods and the introduction of many innovative antipsoriatic drugs. Moreover, many patients with psoriasis are dissatisfied with their current treatment methods and the form with which the drug is applied. The patients complain about skin irritation, clothing stains, unpleasant smell, or excessive viscosity of the preparation. The causes of these issues should be linked with little effectiveness of the therapy caused by low permeation of the drug into the skin, as well as patients’ disobeying doctors’ recommendations, e.g., concerning regular application of the preparation. Both of these factors are closely related to the physicochemical form of the preparation and its rheological and mechanical properties. To improve the quality of patients’ lives, it is important to gain knowledge about the specific form of the drug and its effect on the safety and efficacy of a therapy as well as the patients’ comfort during application. Therefore, we present a literature review and a detailed analysis of the composition, rheological properties, and mechanical properties of polymeric gels as an alternative to viscous and greasy ointments. We discuss the following polymeric gels: hydrogels, oleogels, emulgels, and bigels. In our opinion, they have many characteristics (i.e., safety, effectiveness, desired durability, acceptance by patients), which can contribute to the development of an effective and, at the same time comfortable, method of local treatment of psoriasis for patients.

Keywords: Psoriasis vulgaris; polymeric gels; topical formulation in treatment psoriasis; drug delivery systems

1. Introduction
1.1. Course and Symptoms of Psoriasis

Psoriasis is a chronic, autoimmune, recurrent systemic disease, in which inflammatory processes are characterized by the appearance of skin symptoms, i.e., scaly lesions and symptoms on joints and tendons [1–3]. Psoriasis is a genetically determined skin condition with polygenic inheritance, occurring in about 2% of the world’s population in both men and women. However, prevalence varies from region to region. The lower prevalence affects Asian and some African populations. In Caucasian and Scandinavian populations, the percentage of people with psoriasis reaches 11% [1,4].

Psoriasis is a non-infectious and non-malignant disease, and its etiology is not fully explained. In addition to the above-mentioned genetic background and immunological disorders, malfunction of the components of the immune system (T lymphocytes and secreted cytokines), the development of the disease is also affected by some environmental factors, age, and sex. The most important environmental factors include injuries (mechanical damage or prolonged skin irritation), bacterial infections, viral infections, untreated...
inflammatory foci in the body, some drugs, alcohol, nicotine, and also emotional stress. More and more often, the relationship between psoriasis and metabolic syndrome is also highlighted. The whole influences the onset of the symptoms, course, and clinical picture of the disease [5,6].

The cause of the formation of the characteristic psoriasis symptoms is an excessive number of cell divisions in the basal layer of the epidermis, and an accelerated, abnormal cycle of maturation of keratinocytes. The process of proliferation and exfoliation of cells in psoriasis due to excessive and abnormal stimulation of the immune system is reduced from a period of about one month (period in properly functioning skin) to about four days. This leads to forming lesions on the skin with various severity, i.e., forms with few small skin lesions or even severe forms of the disease characterized by inflammatory and exudative lesions, which can take a generalized form (psoriatic erythroderma) [7]. These lesions are oval or round, red-brown, or pinkish. The flat lumps with expressive edges and of varying size are covered with silvery or silvery-gray, layering scales, which is formed as a result of cornification of the disease foci. The lesions tend to overlap and form extensive plaques. They usually occur on the skin of limb extensors (mainly elbows and knees), areas near sacrum, buttocks, scalp, hands, and feet. The skin lesions around the scalp also cover the smooth skin of the forehead, neck, or ears [8]. The lesions may be itchy and/or painful [2]. Moreover, accelerated blood flow and vasodilation may cause increased cell growth and division in some patients and this, in turn, results in the characteristic symptom of redness of the lesions and rapid accumulation of dead cells on the skin surface [7]. The lesions can occur at any age. The peak of the disease occurs in the second and third decade of life.

Psoriasis is characterized by a chronic course with a tendency to spontaneous remissions and recurrences of the disease. Psoriatic lesions on the body persist for many years; often, new eruptions replace the old ones. Moreover, between 5 and 20% of the patients develop psoriatic arthritis (Lat. psoriasis arthropatica), which is an inflammatory arthritis caused by psoriasis. Sometimes, psoriasis is mistaken for atopic dermatitis [2,7–14].

In order to determine the intensity and severity of psoriasis, psoriasis area and severity index (PASI) and body surface area (BSA) indexes are used. The former is used to determine the severity of erythema, infiltration, and exfoliation of lesions and their area. The PASI lies in the range between 0 (no changes) and 72 (severe). The PASI <10 is classified as a mild case of psoriasis, PASI in the range 10–20 is classified as moderate, and PASI >20 is classified as a severe case. The BSA shows the percentage of the skin covered by lesions. If we assume that the surface area of the hand is about 1% of the patient’s total skin surface, the BSA in mild psoriasis is <5%. The 5–15% BSA is moderate psoriasis and the BSA >15% describes a severe case [12,15].

There are many types of psoriasis with a clinical picture. The most common form of this disease is plaque-like psoriasis (Lat. Psoriasis vulgaris), which affects about 90% of people with psoriasis. In some studies, two types of Psoriasis vulgaris are distinguished. Type 1 is hereditary, and the disease develops before the age of 40. Type 2 concerns psoriasis in adults, and it has a significantly milder course. The first symptoms occur after the age of 40 [8,10–14]. In addition, other forms of psoriasis can be described, such as guttate, pustular, erythrodermic, or inverse psoriasis [16].

Various treatments are used depending on the type and severity of the disease [1,2,17,18].

1.2. Psoriasis Treatment

The main objective of psoriasis treatment is to achieve a long-term remission within 12–24 weeks of therapy, control of disease activity (decrease in the PASI and BSA), improvement of the quality of the patient’s life, maintenance of their ability to work, prevention of accompanying diseases, and reduction of mortality rate [18].

The type of the therapy used depends on the severity and extent of skin lesions. In addition, the presence of concomitant diseases and possible contraindications [17–19] is
taken into account. In this work, we have focused on discussing therapies against *Psoriasis vulgaris*.

1.2.1. External Treatment—Topical Therapy

Topical therapy is a first-line therapy, and usually, it is sufficient against plaque psoriasis and lighter forms of psoriasis covering up to 25% body surface area. The therapy aims at removing lesions and then inhibiting the excessive proliferation of the epidermis [2,18,20]. Preparations with keratolytic and reducing effect are used topically on the skin [21,22]. In the case of exfoliating treatment, a number of preparations are used, e.g., salicylic acid ointment (5–30% salicylic acid), urea ointment (10–20% urea concentration), brine ointment (5–10%), salicylic acid oil (5–7%; for the scalp), salicylic acid sulfur ointment. The application of keratolytic preparations prior to administering other reducing agents enhances the absorption of further drugs. Reducing agents include primarily dithranol in the concentration between 0.025 and 0.2% or used in a “minute therapy” in the concentration above 2% (maximum application time on the skin is 2 h). Other agents include plant tars (from pine, beech, juniper; concentrations 5–20%), corticosteroids (in creams, ointments, solutions), vitamin D₃ and its derivatives, retinoids (tazarotene 0.05–1% as ointment or gel) [1,2,17,18,20,22]. However, the gold standard for topical treatment of psoriasis is a combination of vitamin D derivative and corticosteroids [23].

The selection of the medicinal substance depends on the location of psoriatic lesions, the patient’s preferences, the cost of treatment, the likelihood of remission, and possible side effects. In some cases, a combination therapy with more than one medicine may be necessary [19,22].

The location of psoriatic lesions in different regions of the body, such as scalp, hand, feet, and mucosal regions, affects the type of drug substance administered, its concentration, and the physicochemical form of the preparation. Preparations in the form of ointments, creams with active substances, such as cypoglin, corticosteroids, or vitamin D derivatives (calcitriol, calcipotriol, and tacalcitol), are applied to the skin of the hands and feet. These preparations can be placed on the skin for a specific period of time, after which they must be washed away by the patient. Many of them should not be used on sowing, irritated, exudative lesions, and in the area of skin folds [18]. In the treatment of scalp psoriasis, local treatment is also basic treatment. Active ingredients such as keratolytic substances, tar, cypogline, retinoids, corticosteroids, or vitamin D derivatives are usually found in a liquid medium such as shampoos, gels, lotions, foams, olive, and emulsions [15]. Contrary to the skin, the mucosal or genital areas are less common in the location of psoriasis. Due to the significant absorption of preparations from this area and potential side effects, these regions require topical application, i.e., corticosteroid preparations (creams) with a lower potency of action. Preparations with high potency are contraindicated due to the risk of skin atrophy and the risk of too much absorption of the drug.

Psoriasis is considered as a T-cell-mediated disease; in this context, an important role is played by vitamin D. This micronutrient is able to modulate innate and adaptive immunity, and it has antiproliferative and pro-differentiative effects on keratinocytes. Alteration of the metabolism of vitamin D may alter the cutaneous barrier integrity and favor an infective and inflammatory condition [24,25].

Sun and brine baths are used to support topical treatment. The latter probably reduce the presence of scales, thus declining the inflammatory mediator overload that can be found in them [20].

Especially during periods of remission, a complementary therapy in the treatment of psoriasis includes also emollients and moisturizing cosmetics as they reduce the patient’s subjective sensations of discomfort and itching (preparations containing, among others, polidocanol). This also results in the increased hydration of *stratum corneum* and restoration of skin barrier function [22,26].

In the literature [27], studies on animals are also available, which are helpful to determine the potential of plant products to be used in psoriasis treatment. These studies
were mostly in vivo, and they were performed on a mouse tail model of psoriasis, which was introduced by Jarret and Spearman [28]. The following substances were studied, among others: ethanolic extract of *Aloe Vera* gel [29], ethanolic extract of *Nigella sativa* [30], ethanolic extract of *Rubia cordifolia* [31], methanol extract of *Smilax china* and isolated flavonoid quercetin [32], *Thespesia populnea* extract [33], hydroalcoholic extract of *Wrightia tincorita* [34], baicalin isolated from *Scutellaria baicalensis* [35], and methanol extract of *Kigelia africana* [36]. Even though most of the studied extracts showed significant percentage reduction of relative epidermal thickness, promoted epidermal differentiation and normal keratinization of keratinocyte, produced significant orthokeratosis, and exhibited a higher antipsoriatic activity as the positive control, the conducted studies provided limited information about their effectiveness and safety in topical treatment of psoriasis, and did not have a significant impact on placing new drugs on the market [27].

In order to increase the effectiveness of topical treatment, phototherapy or photochemical therapy are used in some patients [2,17,37].

The literature data also show that occlusive dressing can be also effective in topical psoriasis treatment. However, the mechanism of how occlusive dressing works has not been fully researched yet. It is assumed that it can be related to the restoration of the skin barrier, hydration of the epidermis, and the reduction of mitotic activity of the epidermis in psoriatic plaques. An important factor may be restoring the granular layer and maintaining calcium gradient in the epidermis for the correct differentiation of cells. The advantage of this treatment method is a lower dose of the drug in comparison with the traditional application to the skin [2,38–42].

Other proposed unconventional therapies of topical psoriasis treatment include grenz rays, *mahonia aquifolium* (Oregon grape), cyclopamine, caffeine, topical 5-fluorouracil, photodynamic therapy, excision, and cryosurgery [20].

### 1.2.2. Systemic Psoriasis Treatment

General treatment (systemic) occurs when the topical therapy is ineffective and in the case of several clinical picture of psoriasis. Systemic treatment can be described as immunosuppression. The following substances are used: retinoids, methotrexate, hydroxyurea, cyclosporine A, fumaric acid and its esters, antibiotics, biological drugs, efalizumab, alefacept, etanercept, infliximab, and adalimumab [1,17,18,43,44]. This treatment carries a risk of serious side effects including liver and kidney disorders, hypertension, or bone marrow immunosuppression.

There is also monoclonal antibody therapy against interleukin 17 (secukinumab, ixekizumab and brodalumab) and interleukin 23 (guselkumab and tildrakizumab). Unlike topical or oral medicines, monoclonal antibodies are administered in injections, intravenously, or intramuscularly [45,46]. Moreover, the price of most of these preparations is very high. The inclusion of glucocorticosteroids in a systemic therapy is recommended in specific cases, e.g., psoriasis leading to erythroderma [1,7,47–49].

In order to reduce side effects, avoid the risks associated with intravenous therapy, or the inconveniences associated with variable pH in the stomach, and the emptying time and hepatic metabolism characteristic of systemic therapy [50], there have also been attempts to introduce systemic medicines, such as cyclosporin, methotrexate, fumaric esters, mycophenolate mofetil as active ingredients in topical preparations [20].

### 1.2.3. Quality of Life of People with Psoriasis

People with psoriasis not only run an increased risk of developing hypertension, hyperlipidemia, obesity, diabetes, and ischemic disease including myocardial infarction [2,51–54], but they are also a group of patients with significantly reduced quality of life [6]. The patients have limited physical fitness, and their mental functioning is similar to those with inflammatory joint diseases, diabetes, hypertension, heart disease, depression, or malignancies [6]. Moreover, people affected by psoriasis are often socially withdrawn,
avoiding places and activities where they would have to reveal areas of the body covered lesions. Psoriasis negatively affects the patients’ sex life [55–58].

Dermatology Life Quality Index (DLQI) is determined on the basis of a questionnaire, and it is used to assess the quality of life, especially the impact of the skin condition on the quality of life and psychosocial functioning. The DLQI is presented on a scale from 0 to 30. A value above 10 means a significant reduction in quality of life. This index, similar to the PASI and BSA, is used to assess the effectiveness of the applied treatment [7,12,21,59].

The quality of life of patients suffering from psoriasis is decreased because this disease remains incurable despite the rapid progress of therapeutic methods and the introduction of many innovative antipsoriatic drugs. Moreover, a great many of patients with psoriasis are dissatisfied or partially satisfied with their current treatment methods. As stated in Teixeira et al. [60], topical treatment is one of the worst aspects of suffering from psoriasis according to the patients. They report difficulties with the acceptance of topical therapies, especially with preparations based on salicylic acid, plant tars, and dithranol due to the unpleasant smell, excessive viscosity, skin irritation, clothing stains, or long-term therapy [15,60].

The causes of these issues should be linked with little efficacy of the therapy caused by low permeation of the drug into the skin [2], as well as patients’ disobeying doctors’ recommendations, e.g., concerning regular application of preparations. Both of these factors are closely related to the physicochemical form of the preparation and its rheological and mechanical properties [50,60,61].

In the topical psoriasis therapy, various vehicles/bases are used, e.g., ointments, creams, solutions, gels, or foams. They are not equally accepted by the patients, and they show different effectiveness. A semi-solid form of the preparation is also preferred for the application to the body, while liquid preparations are mainly applied to the scalp. People affected by skin diseases prefer to use gels and creams rather than sticky and fatty ointments. Furthermore, gels have another advantage, as they can be applied to the skin of both the body and the scalp [60].

When we look for new forms of medicines to improve the quality of life of patients, we should consider patient satisfaction with psoriasis treatment and the fact that up to 70% of the people affected by psoriasis can be treated with topical medicines. That is why it is important that these formulations have specific characteristics; i.e., they:

- Belong to a group of non-Newton shear-thinning fluids; these fluids show greater viscosity when rubbed into a lesion area. Due to increased viscosity, their distribution is limited, so the formulation does not spill over the entire surface of the skin. This makes it possible to create a protective layer on the skin;
- Show thixotropy; the medicinal preparation becomes more liquid with the increased time of the applied forces, but when left undisturbed, it regains its viscosity;
- Have suitable soft consistency, skin adhesiveness, and lower firmness, good spreadability, as these properties mean easy and convenient application, in particular when taking the preparation from the packaging;
- Enhance transport of the medicinal substance deeper into the skin;
- Include cosmetic aspects; i.e., they have a pleasant color, smell, and appearance; do not stain clothing; leave a slight oily feeling on the skin; are easy to remove from the skin; and they have a long shelf life and emollient properties [50,60–63].

A group of preparations for topical application with these properties are polymeric gels. In the case of psoriasis treatment, this group—unlike creams, ointments, or lotions—has a positive effect on the penetration of medicinal substances and their retention in the skin. As a result, this can increase the concentration of these substances in target tissues and cause a significant decrease of hypertrophy and cell damage, which are very common to people with psoriasis. The preparations from the polymeric gel group also increase hydration of the stratum corneum. Their recipes do not have to include additional substances,
such as permeation promoters or solvent, which decreases the risk of skin irritation. They also have appropriate sensory properties [2,64].

The knowledge about the specific form of the drug and its effect on the safety and efficacy of the therapy aids the selection of the drug from a clinical perspective, and it also makes the patients more inclined to follow recommendations. Therefore, in this literature review, we want to summarize the current state of knowledge about the composition, rheological properties, and mechanical properties of polymeric gels and their use as topical dosage form in the treatment of Psoriasis vulgaris. This overview article is limited to a critical analysis of scientific and professional literature, patents excluded. In order to prepare a literature review, search engines such as PubMed, Scopus, Google Scholar, Google Books, and ResearchGate were used. The main search terms concerned Psoriasis vulgaris; topical formulation in treatment psoriasis; drug delivery systems; polymeric gels; hydrogels; oleogels; emulgels; bigels. The literature review focused mainly on analysis of the detailed data concerning the composition, rheological properties, and mechanical properties of polymeric gels and their relationship with the effectiveness of Psoriasis vulgaris treatment. Articles in which there was no information about the composition, mechanical and rheological properties of the polymeric gels, and/or information concerning their effectiveness in psoriasis treatment were excluded from the review.

2. Polymeric Gels and Their Properties

2.1. Polymeric Gels and Their Groups

Polymeric gels are an important class of soft materials, and they are defined as semi-solid formulations (preparations) that are generally composed of at least two components, i.e., a liquid solvent and a solid gelling substance. The solvent forms an external phase and can be hydrophobic or hydrophilic. The solvent is immobilized within the space of a three-dimensional network structure of the gelling agent [50,65–68].

If we take the polarity of the liquid phase as a criterion of division, these gels can be divided into two categories: organogels (containing an apolar solvent) and hydrogels (containing a polar solvent) [69]. In some studies, a third group—xerogels—is also defined. Xerogels are a type of solid-formed gels, which are prepared through drying slowly at the room temperature with an unconstrained shrinkage [65,70].

Another classification criterion for polymeric gels is a cross-linking character. The following types are determined: physical gels, covalently cross-linked gels, and entanglement network gels [65,71].

Recently, there have been studies on new types of gels, such as emulgels (including nanoemulgels), bigels, aerogels, and on their potential in the dermal administration of medicinal substances [50,67,72–76].

2.2. Properties of Polymeric Gels

Polymeric gels have at least one of the following properties: infinite molecular weight, insoluble and infusible, ability to reversibly swell or shrink [65,77]. The most important features of polymeric gels are swelling ability, pseudoplastic rheological behavior, syneresis, electrostatic potential distribution, electrical oscillation, electrical contraction, mechanolectric effect, interaction with oppositely charged surfactants, etc. These properties depend on many factors, the most important of which are constituent polymers, polymeric matrix type, nature of cross-linking size, etc. [65,70,78]. In most cases, gels exhibit stimuli responsive behavior by means of applying external stimuli, such as pH, pressure, temperature, electric field, etc. [79].

Properties of Polymeric Gels Influencing Topical Drug Delivery

Compared to traditional forms of drugs such as ointments and creams, some polymeric gels make it possible to increase the dissociation of the drug and facilitate migration through vesicles due to their high water content [50].
Polymeric gels limit TEWL and hydrate the skin, thus facilitating the transport of the drug to the dermis, deep into the lower tissues, muscles, or capillaries. Another significant factor is that this group of semi-solid formulations can increase the effectiveness of the drugs applied topically, because it stays on the skin longer. The residence time on the skin and occlusive effect of the polymeric gels can be modified by increasing their strength, viscosity, and abrasion resistance after skin application [50,80–82]. This modification is possible by using suitable gels. Gelators at low concentrations should be able to form a structured system of adequate viscosity, showing thixotropy suitable for topical treatment therapy. An optimum balance between the affinity and insolvibility is also needed. This insolvibility acts as a trigger for molecular self-assembly and subsequent organization as a function of concentration and temperature of the gelator. Ideally, the gelling agent must be cheap, easily available, inert, and safe, and it cannot react with other formulation constituents [67,70,83].

The types of polymeric gels, their characteristics, advantages, disadvantages, and their use are summarized in Table 1. Due to the lack of literature data on the use of aerogels and xerogels in the treatment of psoriasis, they were excluded from this literature review. Therefore, the literature data cited for this analysis apply to hydrogels, oleogels, emulgel, and bigels.

**Table 1.** The types of polymeric gels and their specific characteristics, advantages, disadvantages, and use.

| Gel Type | Specific Characteristics | Advantages | Disadvantages | Use | References |
|----------|--------------------------|------------|---------------|-----|------------|
| Hydrogels | three-dimensional hydrophilic polymer networks that can absorb large quantities of liquids or biological fluids | - cheap | - treatment of atopic dermatitis, eczema | - anti-inflammatory products | [2,50,65,67,84–92] |
|          | - the used gelling substances are hydrophilic in nature and contain groups such as hydroxyl groups, carboxyl groups, sulfonic acid groups, amide groups, imide groups | - biocompatible and non-toxic | - anti-inflammatory products | - wound treatment, anti-scar activity | |
|          | - hydrophilic nature, high swelling ability, liquid capturing ability, softness, elasticity, flexibility | - biodegradable | - low mechanical strength | - skin regeneration | |
|          | - versatile: many active substances can be introduced into their recipes, the release of therapeutic substances from hydrogel structures can be activated at any time by changes in temperature, local pH, physical stimuli, as well as by the introducing presence of various types of enzymes | - poor mechanical strength | - due to their hydrophilic nature, the transdermal delivery of the drug can be problematic—difficulty in the introduction of lipophilic substances into the recipe | - dressing materials, dental materials, cell scaffolds, surgical adhesives and fillers, sensors, superabsorbsents, medical implant components | |
|          | - providing a starting point for other gel formulations, such as liposomal gels, emulgels, bigels | - due to their hydrophilic nature, the transdermal delivery of the drug can be problematic—difficulty in the introduction of lipophilic substances into the recipe | - due to the possibility of diffusion of the molecules of the active substance inside them, they are limited ability to be used as drug carriers for active substances with controlled release or as targeted release forms of the active substance and bioadhesive carriers of the drug | |
- possibility of in vivo gelling by introducing first live cells into the hydrogel
- well-tolerated by patients—low irritating potential
- easily spreadable on the skin and water-washable
- non-comedogenic
- do not leave greasy film after application
- cooling-effect
- significant minimization of side effects

- easy to obtain
- cheap
- biocompatible
- thermodynamically stable
- due to an organogelator, they show an increased mechanical strength
- creation of a crystalline network and entrapment of bulk oils

| Organogels (also called oleogels) | | |
|----------------------------------|--|---|
| dispersion medium is an organic liquid (oil or non-polar liquid) | – stability problems at higher temperatures—increased stability | – skin care products |
| non-polar liquid entrapped within a thermoreversible three-dimensional gel network by using an organogelator | – suitable as a vehicle for transdermal drug delivery of lipophilic compounds | – emollients |
| – oleogelators: low-molecular weight components or oil soluble polymers | – enhanced drug penetration through the stratum corneum because of their lipophilic nature—difficult | – compounding base |
| – many of the organogel washing with components perform an water additional function of permeability promoters | – oily texture—unpleasant sensation on the skin | – wound healing |
| – thermoreversible | – difficulty | – drug carriers |
| – viscoelasticity | – another application of oil structuring includes the formation of green lubricants using oleogels as a thickener, paint, coating, and oil spillage treatments | – transdermal systems, parenteral agents, bioadhesive |
| – non-birefringence | – improved | – analgesic, anti-inflammatory effect |
| – optical clarity | – increased | – preparations, rectal products, |
| – more resistant to microbial infections | – more favorable toward lipophilic drugs | – emollients |

[50,65,69,76,93–101]
than hydrogels and emulsions
– the oils used in their production are safe for humans (many of them are used in the food industry)

– simple to prepare and economical in terms of manufacturing because the steps involved in the preparation of the emulgel are simple, no special instruments are required
– can be used as controlled release systems for medicines— they can supply both hydrophobic and lipophilic substances
– thixotropic
– can be easily spread and removed from the surface of the skin
– non-staining
– have an emollient effect
– water soluble
– bio-friendly
– pleasant sensation on the skin—well-tolerated by patients
– long shelf-life
– materials used for its preparation are cheaper and easily available

– mainly emulsion-based gels—these are either an oil/water or water/oil type, which are gelled by incorporating a gelling agent

– preparations with analgesic, anti-inflammatory effect
– skin care—skin softening, moisturizing effect
– used for treatment of various kinds of skin disorders, such as those caused by viral, bacterial, and fungal species (eczema, Herpes simplex, acne)
– suitable for vaginal dryness, dehydration, and redness

– solid-like formulations produced from a combination/mixture of system physically oleogels and a hydrogel stable—reducing skin irritation
– both unmixable phases are independently stabilized with independent gelators
– types of bigels: oleogel dispersed in a

– the absence of an emulsifier promotes phase separation especially with longer storage times
– lack of thermal reversibility—instability at high temperatures

– preparations with analgesic, anti-inflammatory effect
– carrier for antibiotics, such as metronidazole, cicloproxolamine, diltiazem hydrochloride
– moisturizing and care products

[102–113]

[50,67,69,75,114–118]
| hydrogel system, hydrogel dispersed in an oleogel system, bicontinuous bigel, complex bigel | substances deep into the skin |
| --- | --- |
| – synergistic effect of hydrogels and oleogels compared to a single gel | – increased hydration of *stratum corneum* |
| – cooling-effect | – good spreadability |
| – water washability upon application to the skin | – modification of the consistency and degree of release of the drug possible by changing the share of phases and/or type of the gelator |

2.3. Hydrogels

2.3.1. Characteristics and Classification of Hydrogels

Hydrogels are defined as single or multi-component matrices composed of a three-dimensional network of polymer chains (hydrogelators) and water or biological fluid as a solvent, which fills the spaces between macromolecules. Due to their construction, polymeric hydrogels have the properties of both liquids and solids. They have good sorption capacity, biocompatibility, relatively high chemical resistance, and mechanical strength. They have a special capacity to swell and contract in an aquatic environment without a significant irreversible damage to their internal structure [2,91,92]. The water retention in the polymeric structure is closely related to the presence of hydrophilic groups, such as amine, carboxyl, and hydroxyl groups. If the polymer is to form a hydrogel, it should absorb water in at least 10% by mass. Some hydrogels can increase their weight by 1000 times to achieve equilibrium after water absorption [92]. The solvent functions as a transport agent for the diffusion substances inside. The hydrogels have a multiphase form: next to the crystal phase, there is an amorphous phase (swelling) and water [91].

If the type of interaction between polymer chains is considered as classification criterion, hydrogels can be divided into physical and chemical ones [119]. Physically cross-linked gels are gels that are formed by electrostatic action, hydrogen bonds, van der Waals forces, and other intermolecular forces. This type of hydrogels is characterized by a non-homogeneous structure of tangled polymer chains. On the other hand, chemically cross-linked hydrogels are characterized by covalent chemical bonds between polymer chains. These hydrogels are chemically and mechanically resistant, and their disintegration is closely related to the irreversible destruction of the polymer network. Both physical and chemical hydrogels can have many different structural forms, such as cross-linked structures, tangled linear homopolymers, interpenetrating polymer networks (IPN), linear copolymers, and graft copolymers [50,66,92,120–122].

Another type of the classification of hydrogels is the type of substance that forms a three-dimensional network. According to this division, organic and inorganic gels are distinguished. Inorganic gels are usually made of silica and its derivatives, while organic gels are based on polymers. In turn, the hydrogels can be also divided according to the type of the polymer building the gel. The division is as follows: natural gels, formed from substances naturally occurring in nature, such as polypeptides, polysaccharides, and
oligonucleotides; and synthetic gels based on polymers synthesized from derivatives of acrylic and methacrylic acids, and acrylamide [119].

The polymers used to obtain hydrogels are shown in Table 2.

Table 2. Hydrogelators used to obtain hydrogels [88,92].

| Origin                        | Examples                                                                 |
|-------------------------------|--------------------------------------------------------------------------|
| Natural                       | Alginic acid, pectin, hyaluronic acid, dextran sulfate, chondroitin sulfate, chitosan, polylsine, chitin, fibrin, collagen, gelatin, dextran, agar, pullulan |
| Synthetic                     | PEG-PLA-PEG, PEG-PLGA-PEG, PEG-PCL-PEG, PLA-PEG-PLA, PHB, PVA, PHEMA, polyphosphazene, N-vinylpyrrolidone |
| Combination of natural and synthetic hydrogelators | collagen-acrylate, alginate-acrylate, PEO-PPO-PEO |

Legend: PEG, poly(ethylene glycol); PLA, poly(lactic acid); PLGA, poly(lactic-co-glycolic acid); PCL, polycaprolactone; PHB, poly(hydroxy butyrate); PVA, poly(vinyl alcohol); PHEMA, poly(hydroxyethyl methacrylate); PEO, (poly(ethylene oxide); PPO, poly(propylene oxide).

Other classifications of hydrogels divide them by their specific properties, such as pH or temperature sensitivity, biologically active substances (glucose, enzymes, glutathione) [119].

2.3.2. Basic Methods of Synthesis

The first method is classical polycondensation to obtain hydrogels by reacting monomers, oligomers, as well as cross-linking agents with the above-mentioned molecules (Table 2). It is also possible to use polymer chains containing reactive groups to create three-dimensional polymer networks. On the other hand, the design of oligomers or polymers capable of reacting with cross-linking agents makes it possible to obtain a material with the desired degree of cross-linking. The process allows obtaining both physical and chemical gels.

Another method is to transform an existing polymer chain to obtain desired properties. Usually, the hydrophobic chain is hydrolyzed or oxidated, or it undergoes sulfonation to obtain a hydrophilic chain. The reaction product is a physical gel, which after cross-linking can form a chemical gel. The last of these methods allows obtaining physical hydrogels in one of the more interesting forms—polycations. Polymers containing cation groups are called “polycations” and containing anion groups are called “polyanions”. If a polymer contains functional groups with ions, it does not mean that it has hydrogel properties. To achieve this, it is necessary to form a complex. There are two possibilities. The first one is to create a complex of a polycation with a polyanion with the opposite charge or a complex of two oppositely charged polycations. In the first case, an ionotropic hydrogel is obtained; in the second, a hydrogel polycation complex is obtained. The method itself does not introduce any impurities to the hydrogel. The resulting materials are usually sensitive to pH and ionic strength, which is often used in the design of intelligent drug delivery systems [123].

2.3.3. Mechanism

Drugs can be released from hydrogels by diffusion and chemical stimulation. The diffusion mechanism is regulated by movement through the polymer matrix or by bulk erosion of the hydrogel. The chemically stimulated gels swell in response to external cues such as pH and temperature or by enzymatic action. They effectively open their pores for release of the entrapped drug. This type of mechanism can be used for targeted drug release only for diseased tissues. Drug release via diffusion is more common for localized and non-specific drug release [50,124–126].

It is worth mentioning that the selected hydrogels used in biomedical fields can be also suitable bioadhesive hydrogel formulations for cosmetic application to the skin. In
fact, biopolymers used for the preparation of hydrogels for cosmetic applications are similar to those used in biomedical applications (e.g., collagen, gelatin, hyaluronic acid, alginate, chitosan, cellulose, and its derivatives). Biopolymer-based hydrogels are used for developing new cosmetic products, such as “beauty masks”. It is claimed that these masks hydrate the skin, restore its elasticity, and promote anti-aging performance. Superabsorbent hydrogels, in particular acrylate-based materials, are extensively applied in hygiene products to absorb fluids as they are able to keep moisture away from skin, promote skin health, prevent diaper rash, and provide comfort [90,127].

2.3.4. Hydrogels in Psoriasis Treatment

The application of hydrogels in the psoriasis treatment has many advantages, such as reducing the side effects of drugs due to higher bioavailability of medicines. This allows the use of a lower dose, protection against degradation, and highly controlled release of drugs. Unlike the typical physicochemical forms such as creams, ointments, or lotions, hydrogels can effectively promote the penetration of many medical substances, which often have different molecular weight controlling their retention in individual skin layers and target tissues. Moreover, a positive effect of treatment with hydrogels may also be the restoration of the skin barrier, hydration of the epidermal layer, and the reduction of the mitotic activity of the epidermis in psoriatic plaques.

The hydrogels systems reported in the literature for psoriasis treatment applications are summarized in Table 3.

| Solvent | Hydrogelator | Total Concentration of Hydrogelator | Additives | Drug | Key Rheological/Key Mechanical/Spreadability Properties | Key Findings of Effectiveness of Action | Ref. |
|---------|--------------|------------------------------------|-----------|------|-------------------------------------------------------|---------------------------------------|------|
| Water   | aloe vera leaf gel | 98% | xanthan gum, potassium sorbate, sodium benzoate, sodium sulfate, citric acid | aloe vera gel no data available | - The score sum of erythema, infiltration, and desquamation decreased in 72.5% of the aloe vera-treated sites compared with 82.5% of the placebo-treated areas from week 0 to week 4, which was statistically significant in favor of the placebo treatment. | - Ex vivo skin permeation tests show how these gels successfully promote the drug permeation and retention inside the skin for reaching their therapeutic target, while in vivo experiments demonstrate that they decrease the hyperplasia and reduce the macroscopic tissue damage typically observed in psoriatic skin, significantly more than the drugs in solution. | [128] |
| Water and/or ethanol | dicationic bisimidazolium amphiphiles | 5 mg/mL | - | - | - Amplitude sweep tests show that the tacrolimus, phase angle for all methotrexat samples across the e sodium Linear salt, gemcitabine (LVR) was relatively hydrochloric low (17°–20°). As well, de, G' values are higher than G'' ones in all samples. The results for these two parameters indicate that the elastic (solid- like) component is prevalent over the viscous (fluid-drugs not only dissolved at like one. | - Gels can incorporate | [64] |
| Water   | carboxymethylcellulose | 0.5% w/w  | NLC (Nanostructured Lipid Carriers) composed of glyceryl monostearate and/or oleic acid as lipid constituents | The spread diameter was found to be 6.8 for both formulations, which indicated good spreadability of carrier loaded gels. |
|---------|------------------------|-----------|--------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|
|         |                        |           | also 72% of either gemcitabine or methotrexate, and 38% of methotrexate, and 38% of tacrolimus, are found within their fibers. This unique fiber-incorporation behavior acts as a packaging that protects the drug, and more importantly, it influences a Two-Phase Exponential drug release profile, in which the first phase corresponds to the drug dissolved in the interstitial space of the gel, and the second phase corresponds to the drug exiting from the fibers. |
|         |                        |           | - Frequency sweep tests were performed in these gels at a constant shear stress of $\tau = 0.5$ Pa for being within the LVR, finding also that, independently of the frequency applied, $G'$ is higher than $G''$, which confirms the solid-like behavior of these gels. |
|         |                        |           | - The pH of SLN and NLC hydrogel was determined to be 6.8 and 6.7, respectively, suggesting good skin compatibility. |
|         |                        |           | - The primary skin irritation studies indicated that MTX-loaded SLN or NLC hydrogels resulted in no erythema. It can be concluded that NLC represents a promising particulate carrier having prolonged drug release, improved skin permeation. |
|         |                        |           | - Skin permeation study of MTX-loaded SLN and NLC hydrogels showed prolonged drug release up to 24 h. |
|         |                        |           | - The skin drug deposition study showed the greatest deposition of drug enriched NLC hydrogel (28.8%) when compared to plain drug enriched hydrogel (11.4%) and drug enriched SLN hydrogel (18.6%). |
|         |                        |           | - In vivo studies showed complete clearance of parakeratosis by treatment with the prepared NLC formulation. |
|         |                        |           | - NLC-based gel as compared to marketed formulation following Higuchi release kinetics. The skin deposition of the |
MF-loaded, NLC-based hydrogel was found to be 2.5 times higher than the marketed formulation.

- The drug content was found to be uniform throughout the formulated gel with the range of 92.32% ± 0.43, and the average value allowed the process adopted to prepare the gel to be capable of giving reproducible results.
- The prepared topical gel formulation with a PP extract released a maximum of 59.11% ± 0.512% of the extract over a period of 6 h, which shows that the gel formulation can control the release of the drug for a longer period of time.
- The imiquimod-induced psoriatic mouse model showed a prominent antipsoriatic activity of the extract as evident through index grading.
- Treatment with EPP confirmed a marked recovery from psoriasis in the treated groups, as there was a considerable diminution in the thickness and scaling of the skin. This was also confirmed through reduced grading of the PASI scale of the treated groups.
- For the topical treatment with EPP, the result of histopathology clearly shows that regeneration in the tissue integrity was observed with greater collagen content, angiogenesis, keratinization, fibroblast proliferation as compared to the control groups.

Water | carbopol 934 | no data available | methyl parabens, propylene glycol | Hydroalcoholic extract from *Pongamia pinnata* (PP) leaves | The viscosity of the gel was found to be 2100 cps to 1400 cps at 1 rpm to 20 rpm. The spreadability was found to be $9.6 \pm 0.53$ g/s. | [131]

Water | carbopol 940 | 1–4% w/v | ethanol, propylene glycol, methyl paraben, propylparaben, EDTA disodium | methanolic extract of *Ricinus Communis* | The in vitro diffusion study carried out in a diffusion cell for 24 h showed F9 formulation with maximum drug release (96.11%) as compared to other gel formulations. | [132]
Due to their hydrophilic nature, hydrogels have a limited capacity of receiving hydrophobic drugs. That is why there are many literature reports on hybrid combination of a hydrogel structure with colloidal nanocarriers as potential systems for drug delivery. The presence of nanodispersion in a hydrogel matrix will increase the bioavailability of hydrophobic substances, e.g., synthetic corticosteroid mometasone furoate [130] by encapsulating them in a hydrophobic core of lipid nanoparticles. On the other hand, hydrogel presence increases the viscosity of the system, and this influences the applicability and sensory properties as well as prolongs contact time with the skin. Moreover, the nanocarrier/hydrogel matrix systems have increased controlled release, which prolongs the exposition of the skin to the active agent [129,130]. It is also worth noting that when hydrogels are used as the carriers of lipid nanostructures, it is possible to obtain a preparation for topical application with a methotrexate (MTX) immunosuppressant [129], which is used in the systemic treatment of psoriasis. Tripathi et al. showed that this both limited

| Water | carbopol 934 | 0.5–2% |
|-------|-------------|--------|
|       | - The viscosity of the studied formulations was 1210–1511 Cps<br>- Spreadability reached 30.66–54.3 mm | Samples F2, F3, and F9 showed a maximum release as compared to F1, F4, F5, F6, F7, and F8. This may be attributed to the percentage of carbopol 940 present in their composition. Carbopol contributes to the drug release of the gel formulation, and a decrease in the percentage of carbopol 940 causes an increase in the percentage of drug release. The optimal percentage of Carbopol 940 is 1%.<br>- There are no in vivo studies concerning the effectiveness of the applied extract in psoriasis treatment |}

- Berberine hydrochloride obtained from Tinospora cordifolia plant
- Viscosity range for preparations 2590–4494 cP<br>- Spreadability 14.06–28.09 g.cm/s
- The concentration of carbopol influenced the consistency of the studied gel: low concentration—formulation becomes similar to a thick liquid only, not as a semi-solid substance. 2% concentration gives better gel properties, but at higher concentration, the gel becomes thick and non-homogenous with poor spreadability.<br>- The mechanism of drug release was found to be non-Fickian.<br>- It was concluded from the results that the permeation of berberine hydrochloride hydrogel was enhanced by Transcutol P in two concentrations (0.1% and 0.2%).
- There are no in vivo studies concerning the effectiveness of the obtained hydrogel in psoriasis treatment.
systemic side effects of the application of this drug and had a limited irritating effect in comparison with a typical hydrogel with MTX. Moreover, hydrogels are systems which, when an appropriate hydrogelator is chosen (e.g., dicationic bis-imidazolium amphiphiles), enable the simultaneous introduction of a drug combination for psoriasis treatment, i.e., corticosteroid derivatives and vitamin D analogs, to the recipe [64]. Hydrogels also allow obtaining the formulations that are based on plant extracts [131–133].

In the literature, there are also reports on the study of the appropriateness of hydrogels in occlusive dressing for psoriasis treatment and on the sensations of the patients during the therapy [2,42]. However, there are no data in the literature about the applied hydrogels (that is why they were excluded from Table 2). The authors claim that, in contrast to occlusive dressing based on hydrocolloids, there are no issues with poor adhesion, irritation, skin injuries, tissue maceration, or bacterial infections and allergic reactions [2,42].

2.4. Oleogels

2.4.1. Oil Structuring and Types of Oleogelators

Oleogels (or organogels) are solid-like systems based on gelation of organic solvents (e.g., oil or non-polar liquid) via low-molecular-weight components or oil-soluble polymers. These compounds are known as organogelators, and they produce a thermoreversible three-dimensional gel network, which traps liquid organic solvents [50,134–137]. This transformation is usually caused by a physical phenomenon, i.e., surface and capillary forces, without affecting the chemical properties of the liquid phase. Usually, the bulk structure of organogels comes from the self-assembly of gelator molecules into a crystal lattice, micelles fibrils, or aggregates, which eventually arrange themselves to form a 3D network [50,67,138–140].

In the literature, two main criteria for the classification of oleogels are used. The first one is the type of the used oleogelator, and the second is the amount of oleogelator used to obtain oleogel. As a result, if we take into account the gelling agent, there are oleogels formed with low-molecular weight oleogelators (LMOGs) and high-molecular weight oleogelators. On the other hand, oleogels can be divided on the basis of the number of the used oleogelators into single-component or multi-component (i.e., mixed) organogels [67,69,100].

Depending on the mechanism of the formation of the three-dimensional skeleton, oleogels are categorized into fluid-filled structure and solid fiber-based oleogels [141].

Gelling substances with low molecular mass include, among others: organic solvents (e.g., benzene, hexane) [134]; edible and vegetable oils compatible with the skin (e.g., sweet almond oil, cod liver oil, olive oil) [136,142,143]; waxes: candelilla wax, rice bran wax, carnauba wax, sugarcane wax, sunflower wax, beeswax [144,145]; colloidal silica [81,146]; lecithin [67,100,147,148]; fatty acids, fatty alcohols, and esters of fatty acids and/or their mixtures [136,149–152]; phytosterols [153]; ceramides [154]; surfactants [67,100,155]. The group of oleogelators with high molecular mass include polysaccharides, especially soluble in water (hydroxypropyl methylcellulose, ethylcellulose), proteins, polymers (e.g., poly(ethylene glycol), polycarbonate, polyesters, and poly(alkylene)) [73,100,156–158].

According to Shakeel et al. [67], the selection of the organogelator to the system should take into account the optimal balance between the affinity and insolubility of the organogelator in the oil phase. This insolubility acts as a trigger for molecular self-assembly and subsequent organization as a function of concentration and temperature of the gelator. However, excessive insolubility of the gelator (i.e., stronger gelator–gelator interactions) results in precipitation of aggregates (i.e., phase separation). Therefore, a suitable balance between gelator–gelator and oil–gelator interactions ensures the formation of a continuous 3D network of gelator molecules and subsequent entrapment of the oil phase. Hence, the process of gelation comprises of molecular interaction at primary, secondary, and tertiary levels.
2.4.2. Production Methods of Oleogels

Usually, oleogels are formed with a direct method, i.e., by introducing the organogelator into the oil phase at the temperature that is higher than its melting point. Other way of obtaining such systems is a multi-step solvent exchange method, which, in short, involves the modification of the polarity of the organic phase by replacing the already existing continuous phase with a new phase. Furthermore, organogels can be produced either by the association of small molecules in the oil phase or by the crosslinking/self-assembly of polymers in any other solvent [67,159,160]. The oleogels obtained with the direct method are used to produce bigels.

2.4.3. Mechanism

Due to the presence of liquid organic phase, organogels are used to the local delivery of lipophilic substances. As a result of the lipophilic nature, they ensure greater solubility of hydrophobic active substances. Moreover, organogel exerts both local and systemic effects through percutaneous absorption enhanced by the presence of penetration enhancers such as fatty acids, surfactants, glycols, essential oils, and terpenes. Fatty acids moieties are believed to create separate domains, which are highly permeable pathways and help the penetration of fatty acids into the lipid bilayer of the stratum corneum. Surfactants and phospholipids present in the organogels cause swelling of the stratum corneum and this leads to higher permeation of the drug. Organogels, especially those based on lecithin, also can solubilize substances with different physicochemical properties; they are biocompatible, thermodynamically and chemically stable, have thermoreversible nature, and have good spreadability on the skin. Thanks to a lack of water, they are resistant to microbial contamination and insensitivity to moisture. They are also characterized by low maintenance cost [30,86,94–97,161].

2.4.4. Utilization of Oleogel Systems in Psoriasis Treatment

The variety of organogelators and their properties (suitability for drug delivery systems, ability to form a crystalline network at low concentrations (<10%), easy availability, low price) [67,155] mean that the oleogels can be used as dermatological substrates and preparations for local treatment of psoriasis. Nevertheless, only a few studies have been published in the literature on the use of oleogels in psoriasis treatment.

The use of oleogels in psoriasis treatment is summarized in Table 4.

| Solvent | Organogelator | Total Concentration of Gelators % Mass | Drug Employed | Additives | Key Rheological/Key Mechanical Properties | Key Findings of Effectiveness of Action | Ref. |
|---------|---------------|--------------------------------------|---------------|-----------|------------------------------------------|------------------------------------------|------|
| Liquid paraffin | hydrogenated castor oil | no data available | Calcipotriol, Betamethasone | Polyoxypropylene 15 stear, alpha tocopherol, BHT | oleogel presented less pronounced shear thinning behavior with power law index (n) lower than 1; oleogels showed no thixotropy; oleogel exhibited the lowest values of adhesiveness and firmness out of tested physicochemical forms | the formulations with lower consistency, lower firmness and adhesiveness, such as creams and gels, were associated with higher patient satisfaction; textural analysis (adhesiveness, firmness), in particular spreadability and rheological characteristics, could be used in the prediction of patients’ satisfaction with topical treatment | [60] |
| Medicinal oleogel: M. chamomilla oil, C. pepo seed oil | colloidal silica | 5% | – | – | the study (clinical study of 40 patients with mild to moderate plaque psoriasis) was limited only to the assessment of the effectiveness of the preparation against placebo | PASI for the oleogel were significantly lower than in the placebo group. In accordance with PGA results, 35% of the patients using oleogel had a significant improvement of the skin condition against 0% of the placebo group | [162] |
Teixeira et al. [60] carried out a study to determine the mechanical preparation (spreadability, firmness, adhesiveness) and rheological (flow curves) of commercial preparations on the Portuguese market to evaluate patients’ satisfaction with different attributes of the studied formulations and to analyze the association of the patient reports with mechanical properties. Out of 14 selected preparations, only one was an oleogel. The rest of the preparations were hydrogels, ointments, or creams. This undoubtedly shows that oleogels are not a popular physicochemical form to be found on the market. The study is important, because it shows that rheological and mechanical properties influence how the patients follow the recommendations of use. Moreover, the authors have shown that the formulations with lower consistency, lower firmness and adhesiveness, such as creams and gels, were associated with higher patient satisfaction. Since the study concerned marketed preparations with unknown composition, unfortunately, it is not possible to draw conclusions if oleogel form yields better effectiveness than traditional forms of drugs for topical treatment, such as studied creams or ointments.

Similarly, topical chamomile-pumpkin oleogel was not compared with the traditional drug form in Kolahdooz et al. [162], which also does not enable us to conclude whether the oleogel form improves Psoriasis vulgaris treatment. The active substances in the oleogel were M. chamomilla oil (47.5% mass) and C. pepo seed oil (47.5% mass). The authors claimed that the effectiveness of the therapy was due to the following components: flavonoids, terpenoids, or linoleic acid.

The drugs for topical psoriasis treatment, such as salicylic acid, have low solubility in water. However, in the literature, there is only one study in which the authors tried to use an oleogel as a substrate for keratolytic agents. The study was conducted by Rehman and Zulfakar [163]. Salicylic acid and benzoyl peroxide were introduced into the recipe of oleogels based on fish oil to limit their side effects after the application: erythema, skin dryness, itchiness, or irritation. The selection of the oil was not random. Fish oil increases the anti-inflammatory effect of corticosteroids (used in topical treatment of psoriasis) and it contains also omega-3 polyunsaturated fatty acids, which also enhance the anti-inflammatory activity. Moreover, fish oil increases the penetration of active ingredients deep into the skin. The results from this study showed that fish oil significantly enhanced the topical delivery of BP across the skin. BP fish oil oleogels with 10% w/w beeswax had a greater drug flux and cumulative release compared to other oleogel formulations and BP commercial hydrogel. In the case of salicylic acid, no significant penetration enhancing effects were achieved. According to the authors, in order to achieve equally good results,
it is necessary to modify the oleogel recipe in this case. The authors did not test their preparation on the skin lesions.

2.5. Emulgels

2.5.1. Emulgel Characteristics

Since the 1980s, emulsion gels have been gaining importance in pharmaceutical topical semi-solid dosage forms. Emulgels are either W/O- or O/W-type emulsions that are gellified with the help of one or many gelling agents and composed of two parts, i.e., emulsion and gel [106]. The presence of the gelling agent in the water phase converts a classical emulsion into an emulgel. The incorporation of the gelling agent to a system makes it thixotropic. Gel–sol–gel behavior imparts stability as well as improves the bioavailability of the system [164]. The emulsion itself is a controlled release system where drug particles are entrapped in the internal phase. Dispersed phases act as a reservoir of drug and slowly release the drug in a controlled way through the external phase to the skin. Gel forms a cross-linked network, where it captures small drug particles and provides its release in a controlled manner. Due to its mucoadhesive property, it prolongs the contact period of the medication over the skin. Gels have faster drug release when compared to other semisolid preparations. They have a higher aqueous component that permits a greater dissolution of drugs and also permits easy migration of the drug through a vehicle that is essentially a liquid, compared with the ointment or cream base. However, the major disadvantage of gels is the inability in delivery of hydrophobic drugs. To overcome this limitation, emulgels are prepared, and with their use, even a hydrophobic drug can enjoy the unique properties of gels [112]. The presence of a gelling agent in the water phase converts a classical emulsion into an emulgel. Generally, a direct (oil-in-water) system is used to entrap lipophilic drugs, whereas hydrophilic drugs are encapsulated in a reverse (water-in-oil) system [165]. The incorporation of an emulsion into gel makes it a dual control release system; further problems such as phase separation and creaming associated with emulsion are resolved, and its stability improves. Some inherent emulgel limitations that remain are poor absorption of macroparticles via the skin and entrapment of bubbles during the formulation [113]. However, the newest studies showed the solution to this problem by incorporating highly dispersed emulsions (microemulsions and nanoemulsions) into a gel matrix in order to receive microemulgels [166,167] and nanoemulgels [168–170]. Emulgels are simple to prepare and economical in terms of manufacturing because the steps involved in the preparation of the emulgel are simple, no special instruments are required, and the materials used for its preparation are cheaper and easily available [106].

2.5.2. Methods of Obtaining

An emulgel can be obtained in two ways. In the first method, a gel matrix is obtained at the first stage by combining a gelling agent with an aqueous phase. A pH regulator (e.g., triethylamine) must be added to neutralize the reaction of the preparation. Next, a typical emulsion (O/W type in the case of hydrophobic drugs) is obtained. Then, it is incorporated into the gel matrix to obtain an emulgel [105]. The other method is to introduce a gelling agent as one of the components of the water phase in the emulsion. Then, emulsification is conducted at a given temperature. The pH regulator solution is gradually added to the emulsion to achieve gel formation through the neutralization process [109,165].

2.5.3. Mechanism

Emulgels possess the above-mentioned advantages of both emulsions and gels, and they are well-accepted by patients. They are comparable to the combination of a nanocarrier and hydrogel matrix, and they offer many benefits as transdermal formulations, such as controlled drug delivery and easy administration. These properties enhance patient
compliance. Moreover, this solution improves the rheological and sensory properties of emulsions and facilitates its application to the skin. The addition of rheological modifiers ensures prolonged contact time of the preparation with the skin and increases the skin hydration level by forming, simultaneously, a hydrophilic and hydrophobic film on the skin, thus reducing the transepidermal water loss. This is a very important aspect of skin regeneration. Due to its non-greasy nature, it can be conveniently applied to the skin as compared to other topical formulations such as creams or ointments, which are very thick, greasy, and require excessive rubbing. An emulsified gel has proven to be stable and a better vehicle for hydrophobic or poorly water-soluble drugs (ketoconazole, acyclovir, diclofenac, and calcipotriol) to the skin, thereby broadening the range of delivery systems [108–112].

2.5.4. Emulgels in Psoriasis Treatment

Emulgels for dermatological use have several favorable properties, such as being thixotropic, greaseless, easily spreadable, easily removable, emollient, non-staining, water-soluble, biofriendly, transparent, having longer shelf life, and pleasing appearance [99]. Moreover, these systems have similar characteristics to the lipoprotein structure of the skin, and they are more easily spreadable on wide surfaces, such as psoriatic lesions, compared to creams or ointments [109].

According to previously mentioned properties and mechanisms of action, emulgels are successfully used in the treatment of psoriasis (Table 5).

Table 5. Emulgels systems reported in the literature for psoriasis treatment applications.

| Emulsion Type/Composition | Gelling Agent/Hydrogelator | Total Concentration of the Gelling Agent | Drug | Key Rheological/Key Mechanical/Spreadability Properties | Key Findings of Effectiveness of Action | Ref. |
|---------------------------|---------------------------|-----------------------------------------|------|-------------------------------------------------------|----------------------------------------|-----|
| Emulsion/propylene glycol, Tween 60, methyl paraben, cetyl alcohol, stearyl alcohol, Span 60, liquid, and soft paraffins Cremophor EL | Carbopol 934 P | no data available | Calcipotriol | no data available | – The aim of this study was to develop a new topical drug delivery system of calcipotriol in order to improve the solubility and dissolution characteristics of the drug and reduce the undesirable side effects. – The drug release was significantly increased with the emulgel formulations compared to the commercial cream product. | [109] |
| Emulsion/cocoyl caprylocaprate, polyoxyl 20 cetostearyl ether, liquid paraffin, propylene glycol, PEG 400, isopropyl alcohol, water | Carbopol 940 | 0.6–1.2% | Calcipotriol | The increase of the gelling agent concentration in the formulation causes the decrease of the formulation spreadability. | – Optimized formulation (carbopol concentration was 1%) had shown 86.42 ± 2.0% drug release at the end of an 8 h study. – The release rate through dialysis membrane and rat skin is higher when compared to a commercial calcipotriol ointment. | [165] |
| Microemulsion/ Tween 80, isopropyl alcohol, isopropyl myristate water | Carbopol 940 | 1% w/w | Cyclosporine | The data indicate insufficient adhesiveness and high cohesiveness and gumminess of the prepared microemulsion-gel in comparison to | The ex vivo diffusion study showed improved permeation (>24 h) with the microemulsion gel in comparison to cyclosporine suspension. |
marketed Volini gel. Thus, tailoring of Carbopol content is needed in future studies to achieve the required mechanical characteristics of the microemulsion gel.

| Nanoemulsion/Pluronic F127 | Carbopol 940 | 0.2–1.5 g | leflunomide 1% | Molecules and formulation properties: |
|---------------------------|-------------|-----------|--------------|--------------------------------------|
| Nanoemulsion/Pluronic F127 | Carbopol 940 | 0.2–1.5 g | leflunomide 1% | Nanoemulsion/Capryol 90, Cremophor EL, Transcutol HPPluronic F127 leflunomide – Mechanical properties of the nanoemulgel measured as force–time relationship using mechanical texture characteristics were optimum for its convenient and easy application to the skin surface. Complete mechanical characterization was carried out using Texture Analyzer and hardness, adhesiveness and springiness index were found to be 523 gms, 431 gms and 1.02, respectively. The in vitro cytotoxicity of LFD nanoemulgel in human HaCaT, melanoma A375, and SK-MEL-2 cell lines showed significantly enhanced therapeutic response. In summary, LFD nanoemulgel for transcutaneous delivery will reduce the overall dose and drug consumption by effectively localizing at the applied target site and will ultimately minimize systemic side effects. |
| Emulsion/Capryol 90, Cremophor EL, Transcutol HP | Carbopol 940 | 0.2–1.5 g | leflunomide 1% | Emulsion/Capryol 90, Cremophor EL, Transcutol HPPluronic F127 leflunomide – All formulations have good spreadability and exhibit non-Newtonian behavior with pseudoplastic properties. Carbopol concentrations have direct influence on the viscosity and release of the active ingredients. Optimized formulations were (E1) and (R3) that showed 77.60% and 97.16% mean cumulative % release respectively after 480 min. No skin irritation was noticed. Antipsoriatic activity study showed that (E1) emulgel decreased the number of nucleated cells, which shows significant increase in % orthokeratosis ($p < 0.0001$) in comparison with the control group, while (R3) showed lower effect compared to (E1). The formulated (E1) emulgel (contains: 50% aqueous coffee extract, Myrrh alcoholic extract, Cymbopogon proximus (volatile oil), Nigella sativa seeds total oil, Olibanum alcoholic extract and theophylline) is a promising new herbal formula to treat psoriasis, also (R3) had antipsoriatic effect but lower than (E1). |
| Emulsion/Capryol 90, Cremophor EL, Transcutol HP | Carbopol 940 | 0.2–1.5 g | leflunomide 1% | Emulsion/Capryol 90, Cremophor EL, Transcutol HPPluronic F127 leflunomide – All formulations have good spreadability and exhibit non-Newtonian behavior with pseudoplastic properties. Carbopol concentrations have direct influence on the viscosity and release of the active ingredients. Optimized formulations were (E1) and (R3) that showed 77.60% and 97.16% mean cumulative % release respectively after 480 min. No skin irritation was noticed. Antipsoriatic activity study showed that (E1) emulgel decreased the number of nucleated cells, which shows significant increase in % orthokeratosis ($p < 0.0001$) in comparison with the control group, while (R3) showed lower effect compared to (E1). The formulated (E1) emulgel (contains: 50% aqueous coffee extract, Myrrh alcoholic extract, Cymbopogon proximus (volatile oil), Nigella sativa seeds total oil, Olibanum alcoholic extract) is a promising new herbal formula to treat psoriasis, also (R3) had antipsoriatic effect but lower than (E1). |
### Nanoemulsion Labrafac PG™
- **Labrafac PG™**
- **Tween 20**
- **Transcutol-HS15**
- **Acconon-MC8-2**
- **Solubilizer for Curcumin**

| Solvent | Surfactant | Solubilizer | Curcumin |
|---------|------------|-------------|----------|
| Carbopol 934 | 0.25–1.0% w/w | Transcutol | Curcumin |

- Mean viscosity of formulations 123.85–130.53 cP
- Placebo gel as well as CUR-NEG showed similar resistance and spreadability

– Despite the high solubility of curcumin in acconon-MC8-2, it showed physical incompatibility, while transcutol-HS was found to be compatible with the developed nanoemulsion.
– The release of curcumin from the nanoemulsion follows Korsmeyer–Peppas kinetics with Fickian diffusion and exhibits a 4.87-fold increase in the permeation of curcumin from the developed nanoemulgel.
– The nanoemulgel formulation exhibited quicker and early healing in psoriatic mice compared to curcumin and betamethasone-17-valerate gel.

### Nanoemulsion/ Fish Oil
- **Unitop 100**
- **PEG 400, water**
- **Carbopol 971**
- **Beta Methasone Dipropionate (BD)**

- The obtained hydrogel-thickened nanoemulsion system (HTN) had a viscosity of 98.67 ± 0.06 PaS

– The optimized formulation had a small average diameter (125 nm) with zeta potential of -39 mV, which indicated good long-term stability.
– In vivo anti-inflammatory activity indicated 87.64% and 48.76% inhibition of inflammation for drug-loaded and placebo formulations, respectively.

### Nanoemulsion/ Salmon Fish Oil
- **Tween 80**
- **Transcutol P**
- **Water**
- **Ethyl cellulose**, **Sodium alginate**, **Carbopol 934**, **Carbopol 971**, **HPMC**
- **Betamethasone Dipropionate (BD)**
- **Salicylic acid**

- The obtained hydrogel-thickened nanoemulsion system (HTN) had a viscosity of 98.07 ± 0.07 mPaS.
- As the concentration of the polymer increased, its viscosity increased simultaneously. A small quantity of the gel was pressed between the thumb and index finger and the consistency and homogeneity of the gel were observed.
- Carbopol 971 in HTN resulted in high viscosity and oily droplets might be distributed in the gel network, which might contribute to the enhancement of the stability of droplets in the nanoemulsion.

– It was concluded that Carbopol 940, sodium alginate, and HPMC were not good gel-forming polymers for BD-loaded nanoemulsions.
– Hydrogel containing 1% Carbopol 971 was found to have good viscosity, and the maximum amount of the drug was retained in the skin during the permeation study.
– Overall, all the formulations have low irritation score; hence, [175] they are safe for human use.
– The optimized formulation had a small average diameter (129.89 nm) with zeta potential of 36.09 mV, which indicated good long-term stability.
– In vivo anti-inflammatory activity indicated 85.22% and 33.31% inhibition of inflammation for drug-loaded and placebo formulations, respectively.
The emulsified gel has proven to be stable and a better vehicle for hydrophobic or poorly water-soluble drugs such as calcipotriol [109,165], cyclosporine [167], lefunomide [171], and betamethasone dipropionate [174]. Similarly to hydrogels, emulgels can be a carrier of plant extracts with a potential therapeutic effect [172] or, similar to oleogels, they can contain fish oil, which can additionally act as a penetration enhancer and have an anti-inflammatory effect [175]. If microemulsion is used [129], they can also enable the combination of corticosteroids and substances with keratolytic properties.

The above-mentioned literature also indicates that the data of texture profile analysis and spreadability are routinely used as an analytical tool to evaluate the semi-solid dosage forms such as emulgels. The topical dosage form that is applied to the skin surface should have sufficient mechanical characteristics. If the gelator concentration is too high in the formulation, the spreadability of the formulation decreases [165]. If the gel is too hard and cohesive, it will be difficult to apply it to the skin and, as a result, unacceptable. On the other hand, if the gel has low adhesiveness and cohesiveness, it will spill from the container tube and at the application site [167]. In the case of preparations for treating skin
inflammation, it is therefore very important to select an optimal consistency of gelling substances, because they influence the mechanical and sensory properties, and, as a result, patients’ comfort of use of the formulation.

2.6. Bigels

2.6.1. Types of Bigels and Their Advantages over Other Polymeric Gels

Bigels are uniform semisolid dispersion systems that are obtained by combining hydrogel and oleogel, and they appear as a single gel when seen visually. Both unmixed phases are independently stabilized with independent gelators. The immobilization of the immiscible liquid phase causes a noticeable decrease in the interfacial free energy. Due to the microarchitectural structure, some bigels are also known as biphasic gels [65,115,116,123].

This system has higher stability in comparison to emulsions (o/w and w/o), creams, emulogs, hydrogels, and oleogels. It can be attributed to the formation of extra-fine colloidal dispersion, which results from the immobilization of the mobile phases in a three-dimensional gel network [65,115,116]. It also has characteristic properties (advantages) of oleogels and hydrogels, i.e., cooling effect, enhancement of hydration of the stratum corneum, moisturizing effect, easily spreadability, emollients, and water-washability upon application to the skin, improved drug permeation. These properties are usually the result of synergism of both forms of polymeric gels within a single gel system. Converting oleogels, emulogs, and hydrogels into bigels imparts also good patient compliance without compromising the beneficial effects of the oil. Since bigels have both the water and oil phases, they can transport hydrophilic and hydrophobic active agents. They possess electrical conductivity, which makes them a suitable carrier for iontophoretic drug delivery [50,75,115,116,178]. Bigels may also have some drawbacks, such as destabilization at high temperature, which means these systems are not thermo-reversible [75,179]. The mechanical, structural, thermal, physical, rheological, and electrical properties of bigels have a crucial impact on their application. The modification of the above-mentioned properties is possible by changing the following parameters: organogel/hydrogel ratio, nature and structure of gelling agents, amount of gelators (organogelator and hydrogelator), incorporation of additives/emulsifiers, and type of organic solvent/oil [67,69,75,180,181].

Organogelators and hydrogelators used in the production of bigels are common ingredients of topical semi-solid formulations. Scientists analyzed many different hydrogelators, e.g., branched polysaccharides [182], naturals gum (i.e., xanthan gum, guar gum) [183], Carbopol [115,184], PVA (polyvinyl alcohol) [185], HPMC (hydroxypropyl methylcellulose) [186], sodium alginate [181]; and oleogelators: cetyl alcohol or Span 60, or mixture of different surfactants (Span 60, Tween 80, Span 80, Tween 20) [185], beeswax [163], and hydrophilic colloidal silica particles [146].

Bigels are classified into four categories on the basis of their structural organization and the disposition of organogels and hydrogels. They are oleogel dispersed in a hydrogel system (o/w), hydrogel dispersed in an oleogel system, (w/o), bicontinuous bigel, and a complex bigel. Bicontinuous bigels are formed when the gel formation is carried out at higher proportions of hydrogel/oleogel dispersed in lower proportions of oleogel/hydrogel phase, respectively. Complex bigels are systems in which an organogel/hydrogel is added to an oil-in-water/water-in-oil structured emulsion, and the formation of a complex matrix-in-matrix system was also demonstrated [75,116,117].

Bigel systems are divided into conventional or unconventional systems if they are, respectively, produced with mono-component organogel and hydrogel phases or with multi-component organogel/hydrogel phases [67,75].

2.6.2. Bigel Production Methods

One of the methods of obtaining bigels for drug delivery is to mix a pre-made oleogel and hydrogel in different proportions at a given temperature with high rpm or at high
shear rate [67,69,75,181]. In contrast to multiphase systems, surfactants or emulsifiers are not necessary to obtain bigels, i.e., to ensure their physical stability. Syneresis occurs for bigels if there are large aggregates [50,114]. Since there is no surfactant or emulsifier, bigels differ from creams and emulgels in terms of formulation. The applied production parameters, including mixing speed, mixing temperature, and storage conditions, significantly impact the final properties of the bigel, e.g., viscous modulus and complex modulus values. When it comes to storage conditions, there are two predominant ways: storage of the ready bigel after the individual oleogel and hydrogels have been mixed together, or storage of the oleogel and hydrogel for a specific amount of time before they are mixed [67,75].

2.6.3. Mechanism

The skin penetration mechanism of the active substance is of the same nature as in the case of oleogels and hydrogels. The conventional diffusion of hydrogels and the lipophilic nature of oils along with fatty acid as penetration enhancers will enable the drug to pass through the stratum corneum and produce the topical and transdermal effect on the skin [50]. As far as drug release rate is concerned when compared to traditional systems based on polymeric gels, there is contradictory information in the literature. There are reports showing that bigels have a lower [185–187] and higher [183,184,188] drug release rate. It is worth noting that the mechanical and drug release properties were inversely related to each other [75].

2.6.4. Use of Bigels in Psoriasis Treatment

We have analyzed the studies and research available in the literature, and there are no reports on obtaining the bigels that are strictly aimed at psoriasis treatment, i.e., bigels that are a matrix for transporting active substances, e.g., keratolytic. However, in this review article, we have presented papers that present results with a potential for an adjunctive therapy for the treatment of Psoriasis vulgaris. They are bigels with moisturizing, emollient, and anti-oxidant properties (Table 6).

One of the first published research works with the analysis of the moisturizing effect of bigels was prepared by Almeida et al. [115]. To choose promising candidates for the product for topical application, the stability (6 months of storage time) and texture profile (firmness and adhesiveness) of the samples were determined. Almeida et al. concluded that the type of the oleogel used in production determined the properties of the obtained bigel (the preparations differed in homogeneity as well as glossiness and smoothness) and the tested bigels had a texture profile similar to hydrogels. Oleogels showed higher values in firmness and adhesiveness. The differences between the products’ moisturizing effects were clearer in the first hour. These differences decreased over time. The bigels obtained with lower proportions of oleogel showed an increment of the capacitance limited to two hours after application. The moisturizing effect of the skin up to 4 h was achieved with a bigel containing 10% oleogel on the basis of Span 60 and sweet almond oil, while the tested hydrogel moisturized the skin only for 1 h. The authors explained these differences with the composition of the bigels, especially with the presence of cholesterol and sweet almond oil, which have emollient properties, and also with the fact that the bigels presented a combination of two colloidal phases that simultaneously delivered and built water, with aesthetic qualities of form, and therefore representing synergistic behavior.
Table 6. Bigel systems reported in the literature with potential for psoriasis treatment.

| Solvent                  | Gelator Agent          | Total Conc. of Gelators (wt %) | Drug Employed | Additives                        | Organogel/Hydrogel Ratio (wt/wt) | Key Rheological/Mechanical Properties                                                                 | Key Findings                                                                                                                                                                                                                                                                                                                                 |
|--------------------------|------------------------|--------------------------------|----------------|----------------------------------|----------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sweet almond oil or liquid paraffin | Span 60, Cholesterol, Zinc stearate, silicic acid | 4.2–19.7                         | –              | triethanolamine                  | 2/98, 5/95, 7/93, 10/90, 12/88, 30/70, 50/50, 70/30, 90/10 | – Textural profiles of the analyzed bigels are very similar to a hydrogel.  
- Oleogels presented higher firmness and adhesiveness than bigels and hydrogels. | – Type of the oleogel used in production determines the properties of the obtained bigel (the preparations differed in homogeneity as well as glossiness and smoothness).  
- Depending on the oleogel portion in the bigel, the moisturizing effect was observed after 2 to 4 h.  
- Bigels exhibit cooling effect, good spreadability, water washability (similar to hydrogel) with an enhanced emollience and moisturizing effect.  

| Almond oil               | Span 60                | 16                             | –              | propylene glycol, ethanol, triethanolamine | 20/80, 30/70, 40/60                | – Bigels belong to shear thinning fluids.  
- The increase of viscosity is observed together with the increase of Span 60 concentration in the recipe.  
- Bigel spreadability is affected by oleogel to hydrogel ratio.  
- Bigels were classified as semi-solid because the determined spread diameter was <50 mm. | – Bigels had pH suitable for skin application. No symptoms of skin toxicity (redness, edema), irritation, or inflammation were observed. The formulation can be considered as safe for dermal use.  
- Results of the FTIR analysis suggest lack of chemical interaction between the almond oil organogel and Carbopol hydrogel, as well as the existence of a physical mixture of the two phases.  

Reference: [115] [118]
| Sweet almond oil | Span 65 | Alginate | 23.0 | 50/50 |
|------------------|--------|---------|------|-------|

5,8-dihydroxy-1,4-naphthoquinone (M1)
2,3-dichloro-5,8-dihydroxy-1,4-naphthoquinone (M2)

- Non-Newtonian shear thinning fluids—the nature of the fluids is adequate for semi-solid formulations for topical application.

- Bigels with M1 and M2 substances have high quality, ensure skin protection against the damage caused by oxidative stress-mediated aging and UV radiation.
- Active compounds have found a suitable environment with bigel matrix, so they preserved their antioxidant properties.
- Bigels have pH suitable for skin application.
- Bigel samples present a tridimensional network constituted by interconnected porosity and the pores were regular in size. The porous structure promotes their use for drug delivery.
- They are well evaluated by the patients for the following properties: spreadability, lack of greasy sensation on the skin, absorption rate, give hydration sensation perceived as favorable, and a feeling of freshness. [189]
The bigels on the basis of oleogel from sweet almond oil and with Span 60 organogelator and Carbopol hydrogel were also studied by Andonov et al. [118]. Their study concerned mainly the analysis of stability, spreadability, and microarchitecture of the bigels. Similarly to the above-mentioned studies, they analyzed different oleogel to hydrogel ratios and how they determined the stability and rheological properties of bigels. On the other hand, the study did not concern the moisturizing effect on the skin. Nonetheless, we believe that the potential of such systems in the treatment of, among others, psoriasis has been shown by the authors’ assessment of acute skin toxicity. The authors emphasized in the conclusion that the bigels they had obtained did not show any dermal toxicity, irritation, or inflammation, they had adequate pH, and they could be safely used as semisolid vehicles for topical applications as well as good skin moisturizers.

The permeating belief in both modern dermatology and cosmetology is that it is necessary to transport externally antioxidants, especially if the skin has lesions or is prone to irritation and allergies. Antioxidants have protective properties by limiting the rate of intrinsic skin aging, as well as therapeutic by limiting inflammation, thus decreasing the range of secondary lesions caused by uncontrolled oxidation in the tissue.

The therapeutic effect of antioxidants can be observed in psoriasis, because this is a skin condition in which inflammation occurs with great intensity. Khelifi et al. [190] made the first attempt to introduce new compounds on the basis of 1,4-naphthoquinone with antioxidant properties to a bigel recipe. They obtained active substances (5,8-dihydroxy-1,4-naphthoquinone (M1), 2,3-dichloro-5,8-dihydroxy-1,4-naphthoquinone (M2)) at 1% mass, and these were introduced into pre-manufactured oleogels (sweet almond oil 80%, Span 65 20%) and then combined with alginate (3%) hydrogel to create the bigel. The study also included the assessment of pH, stability, and antioxidant activity (DPPH test, ABTS Assay, Reducing Power Assay, β-carotene Bleaching Test) of the bigels. Their flow properties were also determined. Khelifi et al. also performed the sensory analysis of the bigels. For comparative purposes, they tested both pure active substances (M1 and M2) and blank bigels (without active substances) and a market product—pharmaceutical formulation (cream) with synthetic cetrimide with antioxidant activities. The most important fact is that the physicochemical form of a bigel allowed the transport of new active substances (M1, M2) without losing their antioxidant potential, because, as shown in the study, bigels with M1 and M2 have reported good radical-scavenging activity. The absence of any antioxidant effect of blank bigel guarantees that bigels antioxidant potential is specific to the molecules themselves. This could be explained by the fact that the active compounds have found a suitable environment with bigel matrix, so they preserved their antioxidant properties. The authors claim that their formulations have high quality, protect the skin against damage caused by oxidative stress-mediated aging and UV radiation, which, in our opinion, is significant for topical psoriasis treatment and the use of phototherapy as an adjunct therapy.

Lupi et al. [117] described results that are very important for the development of bigels as cosmetic and pharmaceutical preparations. For the first time, they attempted to obtain a complex bigel by combining a cream (emulgel) for skin care with monoglycerides of fatty acids/olive oil organogels. However, due to their nature, they were excluded from this review. In these works, the authors studied bigels from microstructure (i.e., microscopy and electrical conductivity test) and rheological point of view.

3. Conclusions and Future Perspective

In recent years, we have observed dynamic development of polymeric gels as carriers of drugs for the treatment of Psoriasis vulgaris. This follows from the limitations of particular physicochemical forms that are available on the market as well as from the search for formulations for topical application, which will be safe, effective, easy to obtain, with desirable shelf life, and readily and regularly used by patients. New topical formulations must have appropriate cosmetic elegance such as ease of use, no potential staining on clothing, etc. This progress is undoubtedly related to the tremendous amount of available
gelators and their combinations as well as challenges of topical psoriasis treatment, e.g., psoriatic lesions can have both significantly thickened and thinned epidermis and different morphology of the skin that could increase the diversity in drug absorption; the effective management of psoriasis often requires a combined therapy to achieve optimal response while minimizing side effects [191].

The effectiveness of a drug against psoriasis depends on a variety of physicochemical characteristics of the carrier and the active moiety used, leading to variation in drug absorption and drug efficacy, which makes it impossible to develop a universal carrier for the delivery of an antipsoriatic drug. Oleogels and hydrogels are a starting point for obtaining other forms such as emulgel or bigels to which substances can be introduced with various nature, solubility, origin, and skin penetration rate. The possibility of obtaining such oleogels and hydrogels allows obtaining a great deal of effective formulations, as seen in the literature reviewed by us.

Further research of polymeric gels is important, because it is estimated that as much as 2% of the population suffers from psoriasis, and current topical treatment does not yield satisfactory results. Yet in our opinion, researchers should place greater emphasis on the impact of texture and rheological properties on the effectiveness of the therapy, in particular on tolerability by patients. Moreover, it follows from the above-mentioned literature data that better mechanical and rheological properties are not always associated with enhanced drug release rate. The obtained insight regarding the influence of dosage form on the degree of satisfaction with the treatment could be helpful in supporting the selection of the dosage form in clinical practice. The more the product is focused on the satisfaction with the treatment, the more patients are prone to follow therapeutic recommendations and to achieve good results from the treatment.

**Author Contributions:** Conceptualization, A.K.-P., M.M. writing—review and editing, M.M. funding acquisition. All authors have read and agreed to the published version of the manuscript.

**Funding:** This review was funded by the Regional Operational Programme for the Małopolska Region for 2014–2020 Number: RPMP.01.02.01-12-0186/19, Company: WellNanoPharm.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

**References**

1. Rendon, A.; Schäkel, K. Psoriasis Pathogenesis and Treatment. *Int. J. Mol. Sci.* 2019, 20, 1475, doi:10.3390/ijms20061475.
2. Zagórska-Dziok, M.; Sobczak, M. Hydrogel-Based Active Substance Release Systems for Cosmetology and Dermatology Application: A Review. *Pharmaceutics* 2020, 26, 12 396, doi:10.3390/pharmaceutics12050396.
3. Reich, K. Łuszczycy jako układowa choroba zapalna: Implikacje dla postępowania. *Dermatol. Dyd.*** 2012, 3, 4–15.
4. Parisi, R.; Symmons, D.P.; Griffiths, C.E.; Ashcroft, D.M. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. *J. Investig. Dermatol.* 2013, 133, 377–385, doi:10.1038/jid.2012.339.
5. Reich, A.; Wójcik-Maciejewicz, A.; Smolinski, A.T. Stress and the skin. *G. Ital. Dermatol. Venereol.* 2010, 145, 213–219.
6. Szepietowski, J.; Adamski, Z.; Chodorowska, G.; Gliński, W.; Kaszuba, A.; Placek, W.; Rudnicka, L.; Reich, A. Diagnostics and treatment of *Psoriasis vulgaris*: Guidelines of the Polish Dermatological Society. Part I: Mild *psoriasis, psoriasis* in children. *Przegl. Dermatol.* 2012, 99, 83–96.
7. Partyka, A.; Czopek, A.; Stanisz-Wallis, K.; Zagórska, A. The use of biopharmaceuticals in the treatment of *psoriasis. Postepy. Hig. Med. Doswi.* 2018, 72, 642–658, doi:10.5604/01.3001.0012.2026.
8. Krueger, J.G.; Bowcock, A. Psoriasis pathophysiology: Current concepts of pathogenesis. *Ann. Rheum. Dis.* 2005, 64 (Suppl. 2), ii30–ii36, doi:10.1136/ard.2004.031120.
9. O’Leary, C.J.; Creamer, D.; Higgins, E.; Weinman, J. Perceived stress, stress attributions and psychological distress in *psoriasis*. *J. Psychosom. Res.* 2004, 57, 465–471, doi:10.1016/j.jpsychores.2004.03.012.
10. Hendriks, A.G; van der Velden, H.M; Wolberink, E.A.; Seyger, M.M.; Schalwijk, J.; Zeeuwen, P.L.; de Jong, E.M.; Pasch, M.C.; van Erp, P.E.; van de Kerkhof, P.C. The effect of adalimumab on key drivers in the pathogenesis of psoriasis. *Br. J. Dermatol.* 2014, 170, 571–580, doi:10.1111/bjd.12705.

11. Griffiths, C.E.; Barker, J.N. Pathogenesis and clinical features of psoriasis. *Lancet* 2007, 21, 263–271, doi:10.1016/S0140-6736(07)61128-3.

12. Jablonska, S.; Chorzelski, T. *Choroby Skór By*, 5th ed.; Wydawnictwo Lekarskie PZWL: Warszawa, Poland, 2010.

13. Lowes, M.A.; Bowcock, A.M.; Krueger, J.G. Pathogenesis and therapy of psoriasis. *Nature* 2007, 445, 866–873, doi:10.1038/nature05663.

14. Menter, A.; Griffiths, C.E. Current and future management of *psoriasis*. *Lancet* 2007, 21, 272–284, doi:10.1016/S0140-6736(07)61129-5.

15. Romanśka-Gocka, K. Farmakoterapia łuszczycy. *Farm. Pol.* 2009, 65, 647–654.

16. Dattola, A.; Silvestri, M.; Bennardo, L.; Del Duca, E.; Longo, C.; Bianchi, L.; Nisticò, S. Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review. *Dermatol. Ther.* 2018, 31, e12728, doi:10.1111/dth.12728.

17. Kim, W.B.; Jerome, D.; Yeung, J. Diagnosis and management of *psoriasis*. *Can. Fam. Phys.* 2017, 63, 278–285.

18. Kaszuba, A.; Uczniak, S.; Kaszuba, A. *Dermatologia Geriatryczna Tom I, 1st ed.; Wydawnictwo Czeleś: Warszawa, Poland, 2016;* p. 171.

19. Jacob, A.; Mayer, A.; Augustin, M. Keratolytics and Emollients and their role in the Therapy of *Psoriasis*: A systematic Review. *Dermatol. Ther.* 2015, 5, 1–18, doi:10.1007/s13239-015-0068-3.

20. Bosc, J.D.; Spuls, P.I. Topical treatments in *psoriasis*: Today and tomorrow. *Clin. Dermatol.* 2008, 26, 432–437, doi:10.1016/j.clindermatol.2007.10.025.

21. Krzaczynski, J.; Strzałka-Mrozik, B. Farmakologiczne i niefarmakologiczne metody terapii łuszczycy ze szczególnym uwzględnieniem leków biologicznych. *Farm. Pol.* 2020, 76, 333–343, doi:10.3238/farmpol/125682.

22. Fluhr, J.; Cavallotti, C.; Berardesca, E. Emollients, moisturizers and keratolytic agents in *psoriasis*. *Clin. Dermatol.* 2008, 26, 380–386, doi:10.1016/j.clindermatol.2008.01.015.

23. Dattola, A.; Silvestri, M.; Bennardo, L.; Rizzuto, F.; Dastoli, S.; Patruno, C.; Bianchi, L.; Nisticò, S. A novel vehicle for the treatment of *psoriasis*. *Dermatol. Ther.* 2020, 33, e13185, doi:10.1111/dth.13185.

24. Matteozzi, C.; Paolino, G.; Richetta, A.G.; Calvieri, S. *Psoriasis*, vitamin D and the importance of the cutaneous barrier’s integrity: An update. *J. Dermatol.* 2016, 43, 507–514, doi:10.1111/1346-8138.13305.

25. Visconti, B.; Paolino, G.; Carotti, S.; Pendolino, A.L.; Morini, S.; Richetta, A.G.; Calvieri, S. Immunohistochemical expression of VDR is associated with reduced integrity of tight junction complex in psoriatic skin. *J. Eur. Acad. Dermatol. Venereol.* 2015, 29, 2038–2042, doi:10.1111/jdv.12736.

26. Loden, M. Role of Topical Emollients and Moisturizers in the Treatment of dry skin barrier disorders. *Am. J. Clin. Dermatol.* 2003, 4, 771–788, doi:10.2165/00128071-200304110-00005.

27. Herman, A.; Herman, A.P. Topically Used Herbal Products for the Treatment of *Psoriasis*:—Mechanism of Action, Drug Delivery, Clinical Studies. *Planta Med.* 2016, 82, 1447–1455, doi:10.1055/s-0042-115177.

28. Jarret, A.; Spearmann, R.G. *Psoriasis*. In *Histochemistry of the Skin, 1st ed.; Taverner, D., Trounce, J., Eds.; University Press: London, UK, 1964.

29. Dhanabal, S.P.; Dwarampudi, L.P.; Murugananthan, N.; Vadivelan, R. Evaluation of the antipsoriatic activity of *Aloe vera* leaf extract using a mouse tail model of *psoriasis*. *Phytother. Res.* 2012, 26, 617–619, doi:10.1002/ptr.3589.

30. Dwarampudi, L.P.; Falaniswamy, D.; Nithyananthan, M.; Raghu, P.S. Antipsoriatic activity and cytotoxicity of ethanolic extract of *Nigella sativa* seeds. *Pharmacogn. Mag.* 2012, 8, 268–272, doi:10.4103/0973-1296.103650.

31. Lin, Z.X.; Jiao, B.W.; Che, C.T.; Zuo, Z.; Mok, C.F.; Zhao, M.; Ho, W.K.; Tse, W.P.; Lam, K.Y.; Fan, R.Q.; et al. Ethyl acetate fraction of the root of *Rutia cordifolia* L. inhibits keratinocyte proliferation in vitro and promotes keratinocyte differentiation in vivo: Potential application for *psoriasis* treatment. *Phytother. Res.* 2010, 24, 1056–1064, doi:10.1002/ptr.3079.

32. Vijayalakshmi, A.; Ravichandiran, V.; Velraj, M.; Nirmala, S.; Jayakumari, S. Screening of flavonoid “queretin” from the rhizome of *Smilax china* Linn. for anti-psoriatic activity. *Asian Pac. J. Trop. Biomed.* 2012, 2, 269–275, doi:10.1016/S1672-1691(12)60021-5.

33. Shrivastav, S.; Sindhu, R.; Kumar, S.; Kumar, P. Anti-psoriatic and phyto chemical evaluation of *Thebesia populnea* bark extracts. *Int. J. Pharm. Pharm. Sci.* 2009, I, 176–185.

34. Dhanabal, S.P.; Raj, B.A.; Murugananthan, N.; Praveen, T.K.; Raghu, P.S. Screening of Wrightia tinctoria leaves for anti psoriatic activity. *Hygeia J. Drug Med. 2012, 4, 73–78.

35. Wu, J.; Li, H.; Li, M. Effects of baicalin cream in two mouse models: 2,4-dinitrofluorobenzene-induced contact hypersensitivity and mouse tail test for *psoriasis*. *Int. J. Clin. Exp. Med.* 2015, 8, 2128–2213.

36. Oyedele, F.O.; Bankole-Ojo, O.S. Quantitative evaluation of the antipsoriatic activity of sausage tree (*Kigelia africana*). *Afr. J. Pure Appl. Chem.* 2012, 6, 214–218, doi:10.5897/AJPAC12.014.

37. Menter, A.; Korman, N.J.; Elmets, C.A.; Feldman, S.R.; Gelfand, J.M.; Gordon, K.B.; Gottlieb, A.; Koo, J.Y.; Lebwohl, M.; Lim, H.W.; et al. Guidelines of care for the management of *psoriasis* and psoriatic arthritis: Section 5. Guidelines of care for the treatment of *psoriasis* with phototherapy and photochemistry. *JAAD 2010, 62, 114–135, doi:10.1016/j.jaad.2009.08.026.

38. Friedman, S.J. Management of *Psoriasis vulgaris* With a Hydrocolloid Occlusive Dressing. *Arch. Dermatol.* 1987, 123, 1046–1052, doi:10.1001/archderm.1987.01660320088018.
39. Griffiths, C.E.; Tranfaglia M.G.; Kang, S. Prolonged occlusion in the treatment of psoriasis: A clinical and immunohistologic study. J. Am. Acad. Dermatol. 1995, 32, 618–622, doi:10.1016/0190-9622(95)90347-x.

40. Lotti, T. Occlusive treatment in psoriasis: How does it work? J. Am. Acad. Dermatol. 1996, 35, 283–284, doi:10.1016/s0190-9622(96)90360-6.

41. Hwang, S.M.; Ahn, S.K.; Menon, G.K.; Choi, E.H.; Lee, S.H. Basis of occlusive therapy in psoriasis: Correcting defects in permeability barrier and calcium gradient. J. Int. Dermatol. 2001, 40, 223–231, doi:10.1046/j.1365-4362.2001.01158.x.

42. Koo, B.; Hong, J.; Colaco, S. Hydrogel Patch: A New Occlusive Device for the Treatment of Psoriasis—Patient Feedback from a Bilaterally Controlled Study. Psoriasis Forum 2007, 13, 27–30, doi:10.1177/2475530307313a00205.

43. Revicki, D.; Willian, M.K.; Saurat, J.H.; Papp, K.A.; Ortonne, J.P.; Sexton, C.; Cameza. A. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: Results from 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br. J. Dermatol. 2008, 158, 549–557, doi:10.1111/j.1365-2133.2007.08236.x.

44. Lehmann, J.C.; Listopad, J.J.; Rentzsch, C.U.; Igney, F.H.; von Bonin, A.; Hennekes, H.H.; Asadullah, K.; Docke, W.D. Dimethyllumurate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J. Invest. Dermatol. 2007, 127, 835–845, doi:10.1038/sj.jid.5700686.

45. Iannone, L.F.; Bennardo, L.; Palleria, C.; Roberti, R.; de Sarro, C.; Naturale, M.D.; Dastoli, S.; Donato, L.; Manti, A.; Valenti, G.; et al. Safety profile of biologic drugs for psoriasis in clinical practice: An Italian prospective pharmacovigilance study. PLoS ONE 2020, 15, e0241575, doi:10.1371/journal.pone.0241575.

46. Passante, M.; Dastoli, S.; Nisticò, S.P.; Bennardo, L.; Patruno, C. Effectiveness of brodalumab in acrodermatitis continua of Hallopeau: A case report. Dermatol. Ther. 2020, 33, e13170, doi:10.1111/dth.13170.

47. Hawkes, J.E.; Yan, B.Y.; Chan, T.C.; Krueger, J.G. Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis. J. Immunol. 2018, 201, 1605–1613, doi:10.4049/jimmunol.1800013.

48. Gisondi, P.; Del Giglio, M.; Girolomoni, G. Treatment Approaches to Moderate to Severe Psoriasis. Int. J. Mol. Sci. 2017, 18, 2427, doi:10.3390/ijms18112427.

49. Gniadecki, R.; Bang, B.; Bryld, L.E.; Iversen, L.; Lasthein, S.; Skov, L. Comparison of long-term drug survival and safety of biologic agents in patients with Psoriasis vulgaris. Br. J. Dermatol. 2015, 172, 244–252, doi:10.1111/bjd.13343.

50. Rehman, K.; Zulfakar, M.H. Recent advances in gel technologies for topical and transdermal drug delivery. Drug Dev. Ind. Pharm. 2014, 40, 433–440, doi:10.3109/03639045.2013.828219.

51. Lotti, T.; Hergova, J.; Prigano, F. The concept of psoriatic disease: Can cutaneous psoriasis any longer be separated by the systemic comorbidities? Dermatol. Ther. 2010, 23, 119–122, doi:10.1111/j.1529-8019.2010.01305.x.

52. Olivera, M.d.F.; Rocha, B.d.O.; Duarte, G.V. Psoriasis: Classical and emerging comorbidities. An. Bras. Dermatol. 2015, 90, 9–20, doi:10.1590/abd1806-4841.20153038.

53. Henseler, T.; Christoffers, E. Diease comonitance in psoriasis. JADAD 1995, 32, 982–986, doi:10.1016/0190-9622(95)91336-x.

54. Christoffers, E. Comorbidities in psoriasis. Clin. Dermatol. 2007, 25, 529–534, doi:10.1016/j.clindermatol.2007.08.006.

55. Sarkar, R.; Chugh, S.; Bansal, S. General measures and quality of life issues in psoriasis. Indian Dermatol. Online J. 2016, 7, 481–488, doi:10.1016/j.ijderml.2016.02.007.

56. Bienias, W.; Uczniak, S.; Pastuszka, M.; Kaszuba, A. Łuszczyca—Psychologiczne, społeczne i ekonomiczne aspekty schorzenia. Post. Dermatol. Alergol. 2011, 3, 138–143.

57. Grozdev, I.; Kast, D.; Cao, L.; Carlson, D.; Pujari, P.; Schmotzer, B.; Babineau, D.; Kern, D.; McCormick, T.; Cooper, K.D.; et al. Physical and Mental Impact of Psoriasis Severity as Measured by the Compact Short Form-12 Health Survey (SF-12) Quality of Life Tool. J. Investig. Dermatol. 2012, 132, 1111–1116, doi:10.1038/jid.2011.427.

58. Sathyarayana Rao, T.S.; Basavaraj, K.H.; Das, K. Psychosomatic paradigms in psoriasis: Psoriasis, stress and mental health. Indian J. Psychiatry 2013, 55, 313–315.

59. Hongbo, Y.; Thomas, C.L.; Harrison, M.A.; Salek, M.S.; Finaly, A.Y. Translating the science of quality of life into practice: What do dermatology quality life index scores mean? J. Investig. Dermatol. 2005, 125, 659–664, doi:10.1111/j.0022-202X.2005.23621.x.

60. Teixiera, A.; Vasconcelos, V.; Teixeira, M.; Almeida, V.; Azevedo, R.; Torres, T.; Sousa Lobo, J.M.; Costa, P.C.; Almeida, I.E. Mechanical Properties of Topical Anti-Psoriatic Medicines: Implications for Patient Satisfaction with Treatment. AAPS Pharm. Sci. Tech. 2019, 20,1–10, doi:10.1208/s12249-018-1246-2.

61. Kulawik-Pióro, A.; Ptaszek, A.; Kruk, J. Effective tool for assessment of the quality of barrier creams—Relationships between rheological, textural and sensory properties. Regul. Toxicol. Pharmacol. 2019, 103, 113–123, doi:10.1016/j.yrtph.2019.01.026.

62. Thorneloe, R.J.; Bundy, C.; Griffiths, C.E.M.; Ashcroft, D.M.; Cordingley, L. Adherence to medication in patients with psoriasis: A systematic review. Br. J. Dermatol. 2013, 168, 16–31, doi:10.1111/bjd.12039.

63. Iversen, L.; Dauden, E.; Segaert, S.; Freeman, K.; Magina, S.; Rigopoulos, D.; Thaci, D. Reformulations of weel-known active ingredients in the topical treatment of Psoriasis vulgaris can improve clinical outcomes for patients. J. Eur. Acad. Dermatol. Venerol. 2017, 31, 1271–1284, doi:10.1111/jdv.14277.

64. Limón, D.; Talló Dominguez, K.; Garduño-Ramírez, M.L.; Andrade, B.; Calpena, A.C.; Pérez-Garcia, L. Nanostructured supra-molecular hydrogels: Towards the topical treatment of Psoriasis and other skin diseases. Colloids Surf. B Biointerfaces 2019, 181, 657–670, doi:10.1016/j.colsurfb.2019.06.018.

65. Nayak, A.K.; Das, B. Introduction to polymeric gels. In Polymeric Gels Characterization, Properties and Biomedical Applications, 1st ed.; Pal, K., Banerjee, I., Eds.; Woodhead Publishing: Elsevier Ltd.; Cambridge, UK, 2018; pp. 3–27.
66. Shapiro, Y.E. Structure and dynamics of hydrogels and organogels: An NMR spectroscopy approach. Prog. Polym. Sci. 2011, 36, 1184–1253, doi:10.1016/j.progpolymsci.2011.04.002.

67. Shackle, A.; Farooq, U.; Gabriele, D.; Marangoni, A.G.; Lupi, F.R. Bigels and multi-component organogels: An overview from rheological perspective. Food Hydrocoll. 2021, 111, 106190, doi:10.1016/j.foodhyd.2020.106190.

68. Ueda, C.T.; Shah, V.P.; Deredzinski, K.; Ewing, G.; Flynn, G.; Maibach, H.; Marcues, M.; Ryttинг, H.; Shaw, S.; Thakker, K.; et al. Topical and transdermal drug products. Pharmaceut. Forum 2009, 35, 750–764.

69. Shackle, A.; Farooq, U.; Iqbal, T.; Yasin, Lupi, F.R.; Gabriele, D. Key characteristics and modelling of bigels systems: A review. Mater. Sci. Eng. C 2019, 97, 932–953, doi:10.1016/j.msec.2018.12.075.

70. Patil, P.B.; Datir, S.K.; Saudagar, R.B. A Review on Topical Gels as Drug Delivery System. JDDT 2019, 9, 989–994, doi:10.22270/jddt.v9i3.s2930.

71. Bohidar, H.B.; Dubin, P.; Osada, Y. Polymer Gels, Fundamentals and Applications, 1st ed.; American Chemical Society: Washington, D.C., USA, 2003.

72. Redkar, M.R.; Patil, S.V.; Rukari, T.G. Emulgel: A modern tool for topical drug delivery. World J. Pharm. Res. 2019, 8, 586–597, doi:10.20959/wjpr2019-14559.

73. Marangoni, A.G. Oleogels: An introduction. In Edible Oleogels, 2nd ed.; Marangoni, A.G., Garti, N., Eds.; AOCS Press: Urbana, IL, USA, 2018; pp. 1–29.

74. Li, J.; Mooney, D.J. Designing controlled hydrogels for topical drug delivery. Nat. Rev. Mater. 2016, 1, 16071, doi:10.1038/natrevmat.2016.71.

75. Shackle, A.; Lupi, F.R.; Gabriele, D.; Baldiono, N.; De Cindio, B. Bigels: A unique class of materials for drug delivery applications. Soft Mater. 2018, 17, 77–93, doi:10.1080/1539444X.2018.1424638.

76. Sharadha, M.; Gowda, D.V.; Vishal Gupta, N.; Akhila, A.R. An overview on topical drug delivery systems—Updated review. Int. J. Res. Pharm. Sci. 2020, 11, 368–385, doi:10.26452/ijprs.v11i11.1831.

77. Kajiwara, K. Structure of gels. In Gels Handbook the Fundamentals, 1st ed.; Osada, Y., Kajiwara, K., Fushimi, T., Iroasa, O., Hirakawa, Y., Matsunaga, T., Shimomura, T., Wang, L., Ishida, H., Eds.; Elsevier Inc.: Amsterdam, The Netherlands, 2001; Volume 4, pp. 122–171.

78. Sharma, B.; Singh, L.R. Pharmaceutical gels for topical drug delivery: An overview. Int. J. Pharm. Pharm. Sci. 2018, 2, 19–24.

79. Jagur-Grodzinski, J. Polymeric gels and hydrogels for biomedical and pharmaceutical applications. Polym. Adv. Technol. 2010, 21, 27–47, doi:10.1002/pat.1504.

80. Chang, R.K.; Raw, A.; Lionberger, R.; Yu, L. Generic development of topical dermatologic products: Formulation development, process development and testing topical dermatologic products. AAPS J. 2013, 15, 41–52, doi:10.1208/s12248-012-9411-0.

81. Lu, Z.; Fassihi, R. Influence of Colloidal Silicon Dioxide on Gel Strength, Robustness, and Adhesive Properties of Diepoxynac Gel Formulation for Topical Application. AAPS Pharm. Tech. 2015, 16, 636–644, doi:10.1208/s12249-014-0253-1.

82. Zhai, H.; Maibach, H.l. Effects of skin occlusion on percutaneous absorption: An overview. Skin Pharmacol. Physiol. 2001, 14, 1–10, doi:10.1159/000056328.

83. Patel, A.R. Alternative Routes to Oil Structuring. 1st ed.; Springer: New York, NY, USA, 2015; pp. 1–120.

84. Peppas, N.A.; Bures, P.; Leobandung, W.; Ichikawa, H. Hydrogels in pharmaceutical formulations. Eur. J. Pharm. Biopharm. 2000, 50, 27–46, doi:10.1016/S0749-9457(00)00090-4.

85. Chen, X.; Peng, L.-H.; Shan, Y.-H.; Li, N.; Wei, W.; Yu, L.; Li, Q.-M.; Liang, W.-Q.; Gao, J.-Q. Atragaloside IV-loaded nanoparticle-enriched hydrogel induces wound healing and anti-scar activity through topical delivery. Int. J. Pharm. 2013, 447, 171–181, doi:10.1016/j.ijpharm.2013.02.054.

86. Chang, Y.G.; Qinjie, W.; Yunjun, W.; Zhang, D.; Luo, F.; Zhao, X.; Wei, Y.; Qian, Z. A biodegradable hydrogel system containing curcumin encapsulated in micelles for cutaneous wound healing. Biomaterial 2013, 34, 6377–6387, doi:10.1016/j.biomaterials.2013.05.005.

87. Choi, S.; Beak, E.; Davaa, E.; Nho, Y.-Ch.; Lim, Y.-M.; Park, J.-S.; Gwon, H.-J.; Huh, K.M.; Park, J.-S. Topical treatment of the buccal mucosa and wounded skin in rats with triaminolone acetoniode-loaded hydrogel prepared using an electron beam. Int. J. Pharm. 2013, 447, 102–108, doi:10.1016/j.ijpharm.2013.02.053.

88. Du, X.; Zhou, J.; Shi, J.; Xu, B. Supramolecular hydrogels and hydrogels from soft matter to molecular biomaterials. Chem. Rev. 2015, 115, 13165–13307, doi:10.1021/acs.chemrev.5b00299.

89. Gellardo, V.; Munoz, M.; Ruiz, M.A. Formulations of hydrogels and lipogels with vitamin E. J. Cosmet. Dermatol. 2005, 4, 187–192, doi:10.1111/j.1473-2165.2005.00310.x.

90. Mitura, S.; Sionkowska, A.; Jaiswal, A. Biopolymers for hydrogels in cosmetics: Review. Int. J. Mater. Sci. Med. 2020, 31, 50–64, doi:10.1016/j.s1085-602-06390-w.

91. Peppas, N.A.; Merrill, E.W.; Crosslinked poly(vinyl alcohol) hydrogels as swollen elastic networks. J. Appl. Sci. 1977, 21, 1763–1770, doi:10.1002/app.1977.070210704.

92. Hoffman, A.S. Hydrogels for biomedical applications. Adv. Drug Deliv. Rev. 2002, 17, 3–12, doi:10.1016/s1699-2004(01)00239-3.

93. Vintiloiu, A.; Leroux, J.C. Organogels and their use in drug delivery—A review. J. Control. Release 2008, 125,179–192, doi:10.1016/j.jconrel.2007.09.014.

94. Sushil, R.; Santosh, S.B.; Vaibh, U.; Mishra, V.; Gahane, A.; Kain, S.K. Lecithin organogel: A unique micellar system for the delivery of bioactive agents in the treatment of skin aging. Acta Pharmacut. Sin. B 2012, 2, 8–15, doi:10.1016/j.apsb.2011.12.005.
Int. J. Mol. Sci. 2021, 22, 5124

124. Narayanaswamy, R.; Torchilin, V.P. Hydrogels and Their Applications in Targeted Drug Delivery. *Molecules* 2019, 24, 603, doi:10.3390/molecules24030603.

125. Amin, M.C.I.M.; Ahmad, N.; Halib, N.; Ahmad, I. Synthesis and characterization of thermo- and pH-responsive bacterial cellulose/acrylic acid hydrogels for drug delivery. *Carbohydr. Polym.* 2012, 88, 465–473, doi:10.1016/j.carbpol.2011.12.022.

126. Bhattachar, N.; Gunn, J.; Zhang, M. Chitosan-based hydrogels for controlled, localized drug delivery. *Adv. Deliv. Rev.* 2010, 62, 83–99, doi:10.1016/j.addr.2009.07.019.

127. Quatrone, A.; Czajka, A.; Sibilla, S. Thermosensitive Hydrogel Mask Significantly Improves Skin Moisture and Skin Tone: Bilateral Clinical Trial. *Cosmetic 2017*, 4, 17, doi:10.3390/cosmetics4020017.

128. Paulsen, E.; Korsholm, L.; Brandrup, F. A double-blind, placebo-controlled study of a commercial *Aloe vera* gel in the treatment of slight to moderate *Psoriasis vulgaris*. *JADV* 2005, 19, 326–331, doi:10.1111/j.1468-3083.2004.01186.x.

129. Tripathi, P.; Kumar, A.; Kumar Jain, P.; Patel, J.R. Carbomer gel bearing methotrexate loaded lipid nanocontainers shows improved topical delivery intended for effective management of *psoriasis*. *Int. J. Biol. Macromol.* 2018, 120, 1322–1334, doi:10.1016/j.ijbiomac.2018.08.136.

130. Kaur, N.; Sharma, K.; Bedi, N. Topical Nanostructured Lipid Carrier Based Hydrogel of Mometasone Furoate for the Treatment of *Psoriasis*. *Pharm. Nanotechnol.* 2018, 6, 133–143, doi:10.2174/221173850666180523112513.

131. Wadher, K.; Dabre, S.; Gaidhane, A.; Trivedi, S.; Umekar, M. Evaluation of antispirotic activity of gel containing *Pongamia pinnata* extract on Imiquimod-induced *psoriasis*. *Clin. Phytosci.* 2021, 7, 1–6, doi:10.1186/s40816-021-00256-6.

132. Patil, S.C.; Gadade, D.D.; Rathi, P.B. Design, Development and Evaluation of Herbal Gel for Treatment of *Psoriasis*. *JIPBS* 2015, 2, 72–87.

133. Sondhi, S.; Singh, N.; Goyal, K.; Jindal, S. Development of Topical Herbal Gel of Berberine Hydrochloride for the Treatment of *Psoriasis*. *Res. J. Pharma. Dos. Forms Tech.* 2021, 13, 12–18, doi:10.5958/0975-4377.2021.00003.3.

134. Hughes, N.E.; Marangoni, A.G.; Wright, A.J.; Rogers, M.A.; Rush, J.W.E. Potential food applications of edible oil organogels. *Trends Food Sci. Tech.* 2009, 20, 470–480, doi:10.1016/j.tifs.2009.06.002.

135. Schaink, H.M.; van Melssen, K.F.; Morgado-Alves, S.; Kalnin, D.; van der Linden, E. Crystal network for edible oil organogels: Possibilities and limitations of the fatty acid and fatty alcohol systems. *Food Res. Int.* 2007, 40, 1185–1193, doi:10.1016/j.foodres.2007.06.013.

136. Lupi, F.R.; Garbiele, D.; Facciolo, D.; Baldiono, N.; Seta, L.; de Cindio, B. Effect of organogelator and fat source on rheological properties of olive oil-based organogels. *Food Res. Int.* 2012, 46, 177–184, doi:10.1016/j.foodres.2011.11.029.

137. Dassanayake, L.S.K.; Kodali, D.R.; Ueno, S. Formation of oleogels based on edible lipid materials. *Curr. Opin. Colloid Interface Sci.* 2011, 16, 432–439, doi:10.1016/j.cocis.2011.05.005.

138. Patel, A.R. A colloidal gel perspective for understanding oleogelation. *Curr. Opin. Food Sci.* 2017, 15, 1–7, doi:10.1016/j.cofo.2017.02.013.

139. Terech, P.; Weiss, R.G. Low molecular mass gelators of organic liquids and properties of their gels. *Chem. Rev.* 1997, 97, 3133–3159, doi:10.1021/cr9700292.

140. Van Esch, J.H.; Feringa, B.L. New functional materials based on self assembling organogels: From serendipity towards design. *Angew. Chem.* 2000, 39, 2263–2266, doi:10.1002/1521-3773(20000703)39:13<2263::AID-AISEM2263>3.0.CO;2-V.

141. Balasubramanian, R.; Sughir, A.A.; Damodor, G. Oleogel a promising base. *Asian J. Pharm.* 2012, 6, 1–9, doi:10.4103/0973-8598.100118.

142. Almeida, I.F.; Bahia M.F. Evaluation of the physical stability of two oleogels. *Int. J. Pharm.* 2006, 327, 73–77, doi:10.1016/j.ijpharm.2006.07.036.

143. Da Pieve, S.; Calligaris, S.; Panuzzo, A.; Arrighetti, G.; Nicolli, M.C. Effect of monoglyceride organogel structure on cod liver oil stability. *Food Res. Int.* 2011, 44, 2978–2983, doi:10.1016/j.foodres.2011.07.011.

144. Rocha, J.C.B.; Lopes, J.D.; Mascaranhas, M.C.N.; Arellano, D.B.; Guerreiro, L.M.R.; Cunha, R.L. Thermal and rheological properties of organogels formed by sugarcane of candellia wax in soybean oil. *Food Res. Int.* 2013, 50, 318–323, doi:10.1016/j.foodres.2012.10.043.

145. Toro-Vazquez, J.F.; Morales-Rueda, J.A.; Dibildox-Alvadoro, E.; Charó-Alonso, M.; Alonzo-Macias, M.; González-Chávez, M.M. Thermal and textural properties of organogels developed by candellia wax in safflower oil. *J. Am. Oil Chem. Soc.* 2007, 84, 989–1000, doi:10.1007/s11746-007-1139-9.

146. Patel, A.R.; Mankoc, B.; Bin Sintang, M.D.; Lesaffer, A.; Dewettinck, K. Fumed silica-based organogels and aqueous-organic bigels. *RSC Adv.* 2015, 5, 9703–9708, doi:10.1039/C4RA15437A.

147. Nikiforidis, C.V.; Gilbert, E.P. Self-assembles of lecithin and alfa-tocopherol as gelators of lipid materials. *RSC Adv.* 2014, 4, 2466–2473, doi:10.1039/C3RA46584E.

148. Bodenmec, M.; Guo, Q.; Rousseau, D. Molecular and microstructural characterization of lecithin-based oleogels made with vegetable oils. *RSC Adv.* 2016, 6, 47373–47381, doi:10.1039/C6RA04324K.

149. Blach, C.; Gravelle, A.J.; Peyronel, F.; Weiss, J.; Barbut, S.; Marangoni, A.G. Revisitig the crystallization behaviour of stearyl alcohol: Stearic acid (SO:SA) mixtures in edible oils. *RSC Adv.* 2016, 6, 81151–81163, doi:10.1039/C6RA15142F.

150. Gandolfo, F.G.; Bot, A.; Flöter, E. Structuring of edible oils by long chain FA, fatty alcohols and their mixtures. *J. Amer. Oil Chem. Soc.* 2004, 81, 1–6, doi:10.1007/s11746-004-0851-5.
151. Uvanesh, K.; Sagiri, S.S.; Senthilguru, K.; Pramanik, K.; Banerjee, A.; Anis, A.; Al-Zahrami, S.M.; Pal, K. Effect of Span 60 on microstructure crystallization kinetics and mechanical properties of stearic acid oleogels: A in-depth analysis. *J. Food Sci.* 2016, *81*, E380–E387, doi:10.1111/1750-3841.13170.

152. Bin Sintang, M.D.; Danthine, S.; Brown, A.; van de Walle, D.; Patel, A.R.; Tavernier, I.; Rimaux, T.; Devwettinck, K. Phytosterols-induced viscoelasticity of oleogels prepared by using monoglycerides. *Food Res. Int.* 2017, 100, 832–840, doi:10.1016/j.foodres.2017.07.079.

153. Bot, A.; Agterof, W.G.M. Structuring of edible oils by mixtures of γ-oryzanol with β-sitosterol or related phytosterols. *J. Am. Oil Chem. Soc.* 2006, *83*, 513–521, doi:10.1007/s11746-006-1234-7.

154. Rogers, M.A. Ceramide oleogels. In *Edible Oils: Structure and Health Implications*, 2nd ed.; Marangoni, A.G., Garti, N., Eds.; AOCS Press: Urbana, IL, USA, 2018; pp. 235–248.

155. Sanchez, R.; Franco, J.M.; Delgado, M.A.; Valencia, C.; Gallegos, C. Rheology of oleogels based on sorbitan and glycercyl monostearates and vegetal oil for lubricating applications. *Grasas Aceite.* 2011, *62*, 328–336, doi:10.3989/gya.113410.

156. Patel, A.R.; Cludts, N.; Sintang, M.D.; Lesaffer, A.; Devwettinck, K. Edible oleogels based on water soluble food polymers: Preparation, characterization and potential applications. *Food Funct.* 2014, *5*, 2833–2841, doi:10.1039/c4fo00624k. PMID: 25214474.

157. De Vries, A.; Wesseling, A.; vad der Linden, E.; Scholten, E. Protein oleogels from heat set whey protein aggregates. *J. Colloid Interface Sci.* 2017, *15*, 75–83, doi:10.1016/j.jcis.2016.09.043.

158. Suzuki, M.; Setoguchi, C.; Shirai, H.; Hanabusa, K. Organogelation by Polymer Organogelators with a L-Lysine Derivative: Formation of a Three-Dimensional Network Consisting of Supramolecular and Conventional Polymers. *Chem. Eur. J.* 2007, *13*, 8193–8200, doi:10.1002/chem.200700146.

159. Okuro, P.K.; Martins, A.J.; Vicente, A.; Cunha, R.L. Perspective, on organogelator mixtures, structure design, and behaviour, towards or by the crosslinking/self-assembly of polymers in any other solvents. *Curr. Opin. Food Sci.* 2020, *35*, 1–9, doi:10.1016/j.cofs.2020.01.001.

160. Suzuki, M.; Hanabusa, K. Polymer organogelators that make supramolecular organogels through physical cross-linking and self-assembly. *Chem. Soc. Rev.* 2010, *39*, 455–463, doi:10.1039/B910604A.

161. Sreedevi, T.; Ramaya Devi, D.; Vedha Hari, B.N. An emerging era in topical delivery: Organogels. *Int. J. Drug Dev. Res.* 2012, *4*, 35–40.

162. Kolahdooz, S.; Karimi, M.; Esmaili, N.; Zargaran, A.; Kordafshari, G.; Mozafar, N.; Ayati, M.H. Evaluation of the efficacy of a topical chamomile-pumpkin oleogel for the treatment of plaque psoriasis: An intra-patient, double-blind, randomized clinical trial. *Piomed. Res. Ther.* 2018, *5*, 2811–2819, doi:10.15419/bmrat.v5i11.499.

163. Rehman, K.; Tan, C.M.; Zulfakar, M.H.; Development and In-vitro Characterization of Fish Oil Oleogels Containing Benzoyl Peroxide and Salicylic Acid as Keratolytic Agents. *Drug Res.* 2014, *6*, 159–165, doi:10.1055/s-0033-1353531.

164. Lee, C.H.; Moturi, V.; Lee, Y. Thixotropic property in pharmaceutical formulations. *J. Control. Release* 2009, *136*, 88–98, doi:10.1016/j.jconrel.2009.02.013.

165. Naga Sravan Kumar Varma, V.; Maheshwari, P.V.; Navya, M.; Reddy, S.C.; Shivakumar, H.G.; Gowda, D.V. Calcipotriol delivery into the skin as emulgel for effective permeation. *Saudi Pharm. J.* 2014, *22*, 591–599, doi:10.1016/j.jspj.2014.02.007.

166. Sarafian, G.; Afšar, M.; Mansouri, P.; Asgarpanah, J.; Raoulinejad, K.; Rajabi, M. Topical Turmeric Microemulgel in the Management of Plaque Psoriasis: A Clinical Evaluation. *Iran J. Pharm. Res.* 2015, *14*, 865–876.

167. Pandey, S.S.; Maulvi, F.A.; Patel, P.S.; Shukla, M.R.; Shah, K.M.; Gupta, A.R.; Joshi, S.V.; Shah, D.O. Cyclosporine laden tailored microemulsion-gel depot for effective treatment of psoriasis: In vitro and in vivo studies. *Colloid. Surf. B Biointerfaces.* 2020, *186*, 110681, doi:10.1016/j.colsurfb.2019.110681.

168. Miastkowska, M.; Kulawik-Fiöro, A.; Szczurek, M. Nanoemulsion Gel Formulation Optimization for Burn Wounds: Analysis of Rheological and Sensory Properties. *Processes* 2020, *8*, 1416, doi:10.3390/pr8111416.

169. Ahmad, J.; Gautam, A.; Komath, S.; Bano, M.; Garg, A.; Jain, K. Topical Nano-emulgel for Skin Disorders: Formulation Approach and Characterization. *Recent Pat. Antinfect. Drug Discov.* 2019, *14*, 36–48, doi:10.2174/1574891X14666181129115213.

170. Algahtani, M.S.; Ahmad, M.Z.; Ahmad, J. Nanoemulgel for Improved Topical Delivery of Retinyl Palmitate: Formulation Design and Stability Evaluation. *Nanomaterials* 2020, *10*, 848, doi:10.3390/nano10050848.

171. Pand, S.; Pawar, S.; Gangurde, S.; Divate, D. Transcutaneous delivery of lefunomide nanoemulgel: Mechanistic investigation into physicomechanical characteristics, in vitro anti-psoriatic and anti-melanoma activity. *Int. J. Pharm.* 2015, *487*, 148–156, doi:10.1016/j.ijpharm.2015.04.015.

172. Kamal Eldin Hussein, E.E. Topical Herbal Emulgel for Psoriasis Treatment. Available online: http://khar-toumspace.uotk.edu/handle/123456789/26557 (accessed on 4 April 2021).

173. Algahtani, M.S.; Ahmad, M.Z.; Ahmad, J. Nanoemulsion loaded polymeric hydrogel for topical delivery of curcumin in psoriasis. *J. Drug Deliv. Sci. Technol.* 2019, *50*, 101847, doi:10.1016/j.jddst.2020.101847.

174. Sharma, S.; Kumar, A.; Sahni, J.K.; Ali, J.; Baboota, S. Nanoemulsion Based Hydrogel Containing Omega 3 Fatty Acids as a Surrogate of Betamethasone Dipropionate for Topical Delivery. *Adv. Sci. Lett.* 2012, *6*, 221–231, doi:10.1166/asl.2012.2097.

175. Ahmed, S.; Kumar, N. Omega 3—Fatty Acid (Epa and Dha) Rich Salmon Fish Oil Enhance Anti-Psoriatic activity of Glucocorticoid (Betamethasone Dipropionate) in Nano Form. *Int. J. Drug Dev. Res.* 2014, *6*, 61–76.

176. Marwaha, T.K. Formulation design and evaluation of herbal Anti psoriatic Emulgel. *JPSI 2013*, *3*, 30–42, doi:10.7897/2277-4572.02334.
177. Baboota, S.; Alam, S.; Sharma, S.; Sahni, J.K.; Kumar, A.; Ali, J. Nanocarrier-based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis. *Int. J. Pharm. Investig.* 2011, 1, 139–147, doi:10.4103/2220-973X.85963.

178. Cates, M.E.; Clegg, P.S. Bigels: A new class of soft materials. *Soft Mater.* 2008, 4, 2132–2138, doi:10.1039/B807312K.

179. Hamed, R.; AbuRezeq, A.; Tarawneh, O. Development of hydrogels, oleogels and bigels for periodontitis. *Drug Dev. Ind. Pharm.* 2018, 44, 1488–1497, doi:10.1080/03639045.2018.1464021.

180. Kodela, S.P.; Pandey, P.M.; Nayak, S.K.; Uvanesh, K.; Anis, A.; Pal, K. Novel agar-stearyl oleogel based bigels as structured delivery systems. *Int. J. Polym. Mater.* 2017, 66, 669–673, doi:10.1080/00914037.2016.1252362.

181. Martins, A.I.; Silva, P.; Maciel, F.; Pastrana, L.M.; Cunha, R.L.; Cerqueira, M.A.; Vicente, A.A. Hybrid gels: Influence of oleogel/hydrogel ratio on rheological and textural properties. *Food Res. Int.* 2019, 116, 1298–1305, doi:10.1016/j.foodres.2018.10.019.

182. Behera, B.; Sagiri, S.S.; Singh, V.K.; Pal, K.; Anis, A. Mechanical properties and delivery of drug/probiotics from starch and non-starch based novel bigels: A comparative study. *Starch* 2014, 66, 865–879, doi:10.1002/star.201400045.

183. Singh, V.K.; Banerjee, I.; Agarwal, T.; Pramanik, K.; Bhattacharya, M.K.; Pal, K. Guar Gum and Sesame Oil Based Novel Bigels for Controlled Drug Delivery. *Colloid. Surf. B Biointerfaces* 2014, 123, 582–592, doi:10.1016/j.colsurfb.2014.09.056.

184. Singh, V.K.; Anis, A.; Banerjee, I.; Pramanik, K.; Bhattacharya, M.K.; Pal, K. Preparation and characterization of novel carbopol based bigels for topical delivery of metronidazole for the treatment of bacterial vaginosis. *Mater. Sci. Eng. C Mater. Biol. Appl.* 2014, 44, 151–158, doi:10.1016/j.msec.2014.08.026.

185. Behera, B.; Singh, V.K.; Senthilguru Kulanthaivel, M.K.; Paramanik, K.; Banerjee, I.; Pal, K. Physical and mechanical properties of sunflower oil and synthetic polymers based bigels for the delivery of nitromidazole antibiotic—A therapeautic aproach for controlled drug delivery. *Eur. Polym. J.* 2015, 64, 253–264, doi:10.1016/j.eurpolymj.2015.01.018.

186. Ibrachim, M.M.; Hafez, S.A.; Mahdy, M.M. Organogel, hydrogels bigels as transdermal delivery systems for diltiazem hydrochloride. *Asian J. Pharm.* Sci. 2013, 8, 48–57, doi:10.1016/j.ajps.2013.07.006.

187. Sagiri, S.S.; Singh, V.K.; Kulanthaivel, S.; Banerjee, I.; Basak, P.; Bhattachrya, M.K.; Pal, K. Stearate organogel-gelatin hydrogel based bigels: Physicochemical, thermal, mechanical characterizations and in vitro drug delivery applications. *J. Mech. Behav. Biomed. Mater.* 2015, 43, 1–17, doi:10.1016/j.jmbbm.2014.11.026.

188. Satapathy, S.; Singh, V.K.; Sagiri, S.S.; Agarwal, T.; Banerjee, I.; Bhattacharya, M.K.; Kumar, N.; Pal, K. Development and characterization of gelatin-based hydrogels, emulsion hydrogels, and bigels: A comparative study. *J. Appl. Polym. Sci.* 2015, 132, 1–12, doi:10.1002/app.41502.

189. Andonova, V.; Peneva, P.; Georgiev, G.S.; Toncheva, V.T.; Apostolova, E.; Peychev, Z.; Dimitrova, S.; Katsarova, M.; Petrova, N.; Kassarova, M. Ketoprofen-loaded polymer carriers in bigel formulation: An approach to enhancing drug photostability in topical application forms. *Int. J. Nanomed.* 2017, 12, 6221–6238, doi:10.2147/IJNN.S140934.

190. Khelifi, I.; Saada, M.; Hayouni, E.A.; Tourette, A.; Bouajla, J.; Ksouri, R. Development and Characterization of Novel Bigel-Based 1,4-Naphthquinones for Topical Application with Antioxidant Potential. *Arab. J. Sci. Eng.* 2020, 45, 53–61, doi:10.1007/s13369-019-04055-7ff.

191. Salim, N.; Ahmad, N.; Musa, S.H.; Hashim, R.; Tadros, T.F.; Basri, M. Nanoemulsion as dopical delivery systems. *RSC Adv.* 2016, 6, 6234–6250, doi:10.1039/C5RA14946K.